[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 905
1. Amanie J, Pearcey RG, Honore L, Sloboda R: Metastatic adenocarcinoma of the cervix in a delivery-induced traumatic lower vaginal tear. Gynecol Oncol; 2005 Mar;96(3):857-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the cervix in a delivery-induced traumatic lower vaginal tear.
  • BACKGROUND: Noncontiguous vaginal metastasis is rare in cervical cancer and is usually reported in the context of traumatic implantation.
  • Traumatic vaginal implantation of cervical carcinoma has been documented in episiotomy, port site, or incision scars.
  • [MeSH-major] Adenocarcinoma / secondary. Uterine Cervical Neoplasms / pathology. Vagina / injuries. Vaginal Neoplasms / secondary


2. Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI: Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol; 2005 Mar;105(3):494-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysplasia associated with atypical glandular cells on cervical cytology.
  • Most women aged younger than 35 years had a squamous abnormality, whereas women aged 35 years or older had a greater diversity of squamous and glandular lesions and accounted for all cases of endometrial cancer, adenocarcinoma in situ, and cervical adenocarcinoma.
  • [MeSH-major] Cervix Uteri / pathology. Uterine Cervical Dysplasia / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Female. Humans. Middle Aged. Uterine Cervical Neoplasms / pathology. Vaginal Smears


3. Wu YY, Liang MR, Li LY, Zeng SY: [Analysis of 4223 hospitalized patients with cervical cancer during 1990-2007]. Zhonghua Fu Chan Ke Za Zhi; 2008 Jun;43(6):433-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 4223 hospitalized patients with cervical cancer during 1990-2007].
  • OBJECTIVE: To analyze the changes in epidemiology and treatment of hospitalized patients with cervical cancer during 1990-2007.
  • METHODS: Overall, 4648 patients with cervical cancer were diagnosed in our hospital from Jan 1990 to Nov 2007, but only 4223 patients with initial treatment in our hospital were studied retrospectively.
  • (1) The mean age of cervical cancer patients gradually decreased over the past 18 years, from 54.4 years during 1990-1999 to 47.2 years during 2000-2007; the proportion of young patients aged < or = 35 years increased from 4.77% (89/1865) during 1990-1999 to 11.75% (277/2358) during 2000-2007. (2) The proportion of patients with cervical cancer (stage I a-II a) increased from 14.
  • 32% (267/1865) during 1990-1999 to 40.75% (961/2358) during 2000-2007, whereas the proportion of patients with cervical cancer (stage II b-IV) decreased from 85.68% (1598/1865) during 1990-1999 to 59.25% (1397/2358) during 2000-2007. (3) There was no significant change in histopathologic type of cervical cancer, and squamous cell carcinoma of cervix remained the main type of cervical cancer. (4) The treatment pattern of cervical cancer changed significantly: radiotherapy was the main method (75.28%) for cervical cancer during 1990-1999, but during 2000-2007, it was replaced by concurrent chemoradiotherapy (35.79%).
  • CONCLUSIONS: The proportion of young women with cervical cancer was increased during 1990-2007, and at the same period early stage cervical cancer increased, but late stage cervical cancer decreased.
  • It is obvious that chemotherapy has become the important therapy in cervical cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell. Uterine Cervical Neoplasms
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Antineoplastic Protocols. Cervix Uteri / pathology. Combined Modality Therapy. Female. Humans. Incidence. Inpatients. Middle Aged. Neoplasm Staging. Radiotherapy. Retrospective Studies


Advertisement
4. Yokoyama M, Noguchi M, Nakao Y, Ysunaga M, Yamasaki F, Iwasaka T: Antiproliferative effects of the major tea polyphenol, (-)-epigallocatechin gallate and retinoic acid in cervical adenocarcinoma. Gynecol Oncol; 2008 Feb;108(2):326-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiproliferative effects of the major tea polyphenol, (-)-epigallocatechin gallate and retinoic acid in cervical adenocarcinoma.
  • OBJECTIVE: To investigate the combined effect of the major tea polyphenol, (-)-epigallocatechin gallate (EGCG) and retinoic acid (RA) on cervical adenocarcinoma.
  • METHODS: Cell growth rate was examined after treatment for 4, 7 and 10 days with 0-100 microM EGCG and/or 1 microM RA in two cervical adenocarcinoma cell lines, HeLa and TMCC-1.
  • RESULTS: Combining EGCG and RA increased the antiproliferative effect in adenocarcinoma cell lines, whereas EGCG or RA treatment alone caused a less sensitive response in these cells.
  • The combination treatment of EGCG and RA induced apoptosis and inhibited telomerase activity in adenocarcinoma cell lines.
  • These results were consistent with those of an antiproliferative effect of EGCG and/or RA in cervical adenocarcinoma cells.
  • CONCLUSION: Our data suggest that EGCG and RA combined to prevent the carcinogenesis of cervical adenocarcinoma, induce apoptosis and inhibit telomerase activity.
  • The treatments of combining EGCG and RA may be effective in preventing or treating cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Catechin / analogs & derivatives. Tretinoin / pharmacology. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035403.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5688UTC01R / Tretinoin; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


5. Wei M, Liang LZ, Zhang CQ, Xiong Y, Zhang Y, Shen Y, Li JQ: [Correlation of CXCR4/CXCL12 overexpression to lymph node metastasis and chronic inflammation in cervical adenocarcinoma]. Ai Zheng; 2007 Mar;26(3):298-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of CXCR4/CXCL12 overexpression to lymph node metastasis and chronic inflammation in cervical adenocarcinoma].
  • CXCR4/CXCL12 expression in cervical adenocarcinoma has seldom been reported.
  • This study was to investigate the correlation of CXCR4/CXCL12 overexpression to lymph node metastasis and chronic inflammation in cervical adenocarcinoma.
  • METHODS: CXCR4 and CXCL12 immunohistochemical staining and HE staining were performed in 35 specimens of cervical adenocarcinoma, including 8 with lymph node metastasis and 27 without.
  • RESULTS: All 35 specimens of cervical adenocarcinoma expressed CXCR4.
  • CONCLUSIONS: CXCR4 overexpression indicates a higher lymph node metastasis potential of cervical adenocarcinoma.
  • The chronic inflammatory cells in cervical adenocarcinoma are not attracted by CXCL12.
  • [MeSH-major] Adenocarcinoma / metabolism. Chemokine CXCL12 / metabolism. Receptors, CXCR4 / metabolism. Uterine Cervical Neoplasms / metabolism. Uterine Cervicitis / complications

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355795.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Receptors, CXCR4
  •  go-up   go-down


6. Zitzmann S, Krämer S, Mier W, Hebling U, Altmann A, Rother A, Berndorff D, Eisenhut M, Haberkorn U: Identification and evaluation of a new tumor cell-binding peptide, FROP-1. J Nucl Med; 2007 Jun;48(6):965-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It showed binding to follicular thyroid carcinoma as well as anaplastic thyroid carcinoma, mammary carcinoma, cervix carcinoma, prostate carcinoma, and cell lines derived from head and neck tumors, and low affinity could be observed to control cells such as human umbilical vein endothelial cells or immortalized keratinocytes.
  • [MeSH-major] Adenocarcinoma, Follicular / radionuclide imaging. Oligopeptides / pharmacokinetics. Radiopharmaceuticals / pharmacokinetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504878.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FROP-1 peptide; 0 / Iodine Radioisotopes; 0 / Oligopeptides; 0 / Peptide Library; 0 / Radiopharmaceuticals
  •  go-up   go-down


7. Kurshumliu F, Thorns C, Gashi-Luci L: p16INK4A in routine practice as a marker of cervical epithelial neoplasia. Gynecol Oncol; 2009 Oct;115(1):127-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16INK4A in routine practice as a marker of cervical epithelial neoplasia.
  • OBJECTIVE: The aim of this study was to validate the role of p16(INK4a) immunocytochemistry as a marker of cervical epithelial neoplasia in cytology and biopsy samples.
  • Additionally, a selection of paraffin blocks from cases diagnosed previously with squamous intraepithelial lesion and cervical cancer were immunostained.
  • All the cases of cervical adenocarcinoma and mesonephric carcinoma were positive for p16(INK4a).
  • CONCLUSION: p16(INK4a) is a useful additional marker for interpretation of problematic Pap smears and reduces the variability during evaluation of suspicious biopsies of the uterine cervix.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Cervical Intraepithelial Neoplasia / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596140.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


8. Poynor EA, Marshall D, Sonoda Y, Slomovitz BM, Barakat RR, Soslow RA: Clinicopathologic features of early adenocarcinoma of the cervix initially managed with cervical conization. Gynecol Oncol; 2006 Dec;103(3):960-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of early adenocarcinoma of the cervix initially managed with cervical conization.
  • OBJECTIVE: To evaluate the clinicopathologic features of microinvasive adenocarcinoma of the cervix in order to guide the management of patients with this disease.
  • MATERIALS AND METHODS: A retrospective review was conducted of patients diagnosed with early invasive, <or=5 mm stromal invasion, adenocarcinoma of the cervix by a cervical conization between 1992 and 1999 at our institution.
  • Ten patients had positive conization margins for invasive cancer, 3 patients had margins positive for adenocarcinoma in situ, 14 patients had negative margins, and in 6 patients the margin status could not be evaluated.
  • CONCLUSIONS: Historically, the standard management of early invasive adenocarcinoma of the cervix has been controversial, and some clinicians continue to favor radical treatments.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / surgery. Conization / utilization. Outcome Assessment (Health Care). Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / surgery


9. Torres MA, Jhingran A, Thames HD Jr, Levenback CF, Bodurka DC, Ramondetta LM, Eifel PJ: Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter? Int J Gynecol Cancer; 2009 Aug;19(6):1107-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter?
  • OBJECTIVE: The aim of this study was to investigate the relationship between marital status and outcome in women treated with concurrent chemoradiation (CT-RT) for locally advanced cervical cancer.
  • METHODS: We reviewed the records of all women who received CT-RT for squamous or adenocarcinomas of the cervix at the M. D.
  • Anderson Cancer Center between 1998 and 2005.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Marital Status. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / psychology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Disease Progression. Female. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Social Class. Treatment Outcome


10. Manchana T, Triratanachat S, Sirisabya N, Vasuratna A, Termrungruanglert W, Tresukosol D: Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer. Gynecol Oncol; 2006 Mar;100(3):556-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and prognostic significance of COX-2 expression in stage IB cervical cancer.
  • OBJECTIVES: To evaluate the prevalence of cyclooxygenase-2 (COX-2), correlation with various clinicopathologic factors and prognostic significance of COX-2 in stage IB cervical cancer patients.
  • METHODS: 89 paraffin-embedded specimens of patients with stage IB cervical cancer underwent radical hysterectomy and pelvic lymphadenectomy at King Chulalongkorn Memorial Hospital during 1 January 1997-31 December 2002 and were stained with polyclonal goat antiserum against COX-2 using immunohistochemical method.
  • RESULTS: The prevalence of positive COX-2 expression in stage IB cervical cancer in this study was 49.4%.
  • Positive COX-2 expression in cervical adenocarcinoma was higher than squamous cell carcinoma (86.7% versus 40.6%, P < 0.05) and significantly expressed when lymph node metastasis was presented (100% versus 46.4%, P < 0.05).
  • CONCLUSIONS: Strong correlation was found in cervical adenocarcinoma and lymph node metastasis.
  • However, COX-2 expression failed to demonstrate as a significant prognostic factor in stage IB cervical cancer.
  • [MeSH-major] Cyclooxygenase 2 / biosynthesis. Uterine Cervical Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Immunohistochemistry. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging


11. Sláma J, Freitag P, Cibula D, Fischerová D, Janousek M, Pavlista D, Strunová M, Zikán M, Jancárková N: [Glandular premalignant lesions of the uterine cervix]. Ceska Gynekol; 2006 Dec;71(6):446-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glandular premalignant lesions of the uterine cervix].
  • OBJECTIVE: Review of diagnostical and therapeutical methods in glandular premalignant lesions of the uterine cervix.
  • RESULTS: The incidence of invasive adenocarcinomas of the uterine cervix is increasing.
  • Incidence ratio between adenocarcinomas and spinocellular carcinomas is approximately 1:5; however ratio of premalignant lesions reaches only about 1:80.
  • PAP-smear of AGC-NOS/-NEO or adenocarcinoma in situ (AIS) in combination with typical colposcopic appearance raise a suspicion of glandular lesion.
  • Direct biopsy must be always performed to get definite diagnosis.
  • CONCLUSION: Diagnosis of glandular premalignat lesion of the uterine cervix is more complicated in comparison to spinocellular one, however it is getting more significant due to increasing incidence.


12. Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, Avizonis V, Fromm M, Small W, Greven K: Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):111-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
  • PURPOSE: To determine the efficacy and patterns of initial failure for oral celecoxib, intravenous cisplatin, and 5-fluorouracil and concurrent pelvic radiotherapy in patients with locally advanced cancer of the cervix.
  • Of the 78 patients, 24 had treatment failure: 3 with persistent local disease, 9 local only, 2 regional, 4 distant, 1 regional and distant, 1 local and distant, and 2 with local, regional, and distant disease, and 1 had died of cervical cancer without a reported site of first failure and 1 without evidence of disease.
  • CONCLUSION: At 2 years, the estimated disease-free survival and overall survival rate for patients with advanced cervical cancer who underwent a combination of chemoradiotherapy and celecoxib treatment was 69% and 83%, respectively.
  • The identification of more active biologically targeted therapies is warranted for the treatment of advanced cancer of the cervix.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482376.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106633-03; United States / NCI NIH HHS / CA / R01 CA106633; United States / NCI NIH HHS / CA / R01 CA106633-01; United States / NCI NIH HHS / CA / CA106633-02; United States / NCI NIH HHS / CA / R01 CA106633-02; United States / NCI NIH HHS / CA / CA106633-03; United States / NCI NIH HHS / CA / R01 CA106633-04; United States / NCI NIH HHS / CA / CA106633-04; United States / NCI NIH HHS / CA / CA106633-01
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Wisman GB, Nijhuis ER, Hoque MO, Reesink-Peters N, Koning AJ, Volders HH, Buikema HJ, Boezen HM, Hollema H, Schuuring E, Sidransky D, van der Zee AG: Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer; 2006 Oct 15;119(8):1908-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of gene promoter hypermethylation for detection of cervical neoplasia.
  • Current cervical cancer screening is based on morphological assessment of Pap smears and associated with significant false negative and false positive results.
  • Previously, we have shown that detection of hypermethylated genes in cervical scrapings using quantitative methylation-specific PCR (QMSP) is a promising tool for identification of squamous cell cervical cancer.
  • Aim of the present pilot-study was to evaluate presence of hypermethylated genes in cervical carcinogenesis, both in squamous cell as well as adenocarcinomas.
  • Cervical scrapings were obtained from 30 patients diagnosed with cervical cancer (20 squamous cell carcinomas and 10 adenocarcinomas) and 19 women with histologically normal cervices.
  • Overall, CALCA, DAPK, ESR1, TIMP3, APC and RAR-beta2 promoters were significantly more often hypermethylated in cancers than in controls, while adenocarcinomas were more often hypermethylated above the highest control ratio for APC, TIMP3 and RASSF1A promoters.
  • Combining 4 genes (CALCA, DAPK, ESR1 and APC) yielded a sensitivity of 89% (with all adenocarcinomas identified), equal to cytomorphology (89%) and high-risk human papilloma virus (Hr-HPV; 90%).
  • QMSP holds promise as a new diagnostic tool for both squamous cell carcinoma and adenocarcinoma of the cervix.
  • [MeSH-major] DNA Methylation. Promoter Regions, Genetic / genetics. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics


14. Mayun AA, Nggada HA, Audu BM, Pindiga UH, Khalil MI, Musa AB: Histopathological analysis of non-squamous cell malignancies of the uterine cervix in Maiduguri, Nigeria. Afr J Med Med Sci; 2008 Dec;37(4):369-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological analysis of non-squamous cell malignancies of the uterine cervix in Maiduguri, Nigeria.
  • Carcinoma of the uterine cervix is the most common gynaecological malignancy in the developing world despite being largely preventable.
  • The non-squamous cancers of the cervix have not been properly documented in our setting.
  • This study is aimed at reviewing the histological types ofnon-squamous cell cancers of the uterine cervix in relation to the age of presentation, and to analyze some of the histopathological features of adenocarcinomas.
  • Cases of cancer of the cervix histologically diagnosed between January 1989 and December 2004 were extracted from the cancer register of the University of Maiduguri Teaching Hospital.
  • A total of 491 cases of cervical cancers were diagnosed.
  • Out of the 59 non-squamous cervical cancers, 42(71.2%) were endocervical-type adenocarcinomas, while serous papillary, clear cell, and adenosquamous carcinomas comprised 2(3.4%) cases each.
  • Adenocarcinomas are the most common non-squamous malignancies of the cervix and their age of presentation was similar to that of their squamous cell counterpart.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology


15. Rodríguez-Sastre MA, González-Maya L, Delgado R, Lizano M, Tsubaki G, Mohar A, García-Carrancá A: Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix. Gynecol Oncol; 2005 May;97(2):330-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix.
  • OBJECTIVE: The goal of this study was to analyze the cellular distribution and possible alterations of beta-catenin and E-cadherin proteins in different histologic types of uterine cervical cancer and precursor lesions, compared to normal controls.
  • METHODS: We performed an immunochemical staining analysis of the cellular distribution of beta-catenin and E-cadherin proteins in biopsy samples from 20 normal exocervical squamous epithelium, 43 premalignant lesions, and a large series of 126 invasive tumors of different histologic types that included 68 squamous carcinomas, 31 adenosquamous carcinomas, and 27 adenocarcinomas.
  • We found no differences in the distribution of E-cadherin between adenocarcinomas compared with control samples.
  • CONCLUSION: Our findings indicate that cellular alterations of both beta-catenin and E-cadherin are frequent in tumors of the uterine cervix of different histologic types, and support a role for these proteins in cervical cancer development.
  • [MeSH-major] Cadherins / metabolism. Cytoskeletal Proteins / metabolism. Trans-Activators / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervix Uteri / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. beta Catenin


16. Stanojković TP, Konić-Ristić A, Juranić ZD, Savikin K, Zdunić G, Menković N, Jadranin M: Cytotoxic and cell cycle effects induced by two herbal extracts on human cervix carcinoma and human breast cancer cell lines. J Med Food; 2010 Apr;13(2):291-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic and cell cycle effects induced by two herbal extracts on human cervix carcinoma and human breast cancer cell lines.
  • In recent times interest has increased in the complementary medicine of cancer patients.
  • The two extracts investigated exhibited significant antiproliferative activity toward two human breast cancer cell lines (MDA-MB-361 and MDA-MB-453) and a human cervix carcinoma cell line (HeLa) with 50% inhibitory concentration (IC(50)) values ranging from 9.92 to 17.38 microL/mL.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Cell Cycle / drug effects. Plant Extracts / therapeutic use. Uterine Cervical Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. ROSMARINIC ACID .
  • Hazardous Substances Data Bank. URSOLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20170382.001).
  • [ISSN] 1557-7600
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Cinnamates; 0 / Depsides; 0 / Phenols; 0 / Plant Extracts; 0 / Tannins; 0 / Triterpenes; MQE6XG29YI / rosmarinic acid; P3M2575F3F / ursolic acid
  •  go-up   go-down


17. Awale S, Miyamoto T, Linn TZ, Li F, Win NN, Tezuka Y, Esumi H, Kadota S: Cytotoxic constituents of Soymida febrifuga from Myanmar. J Nat Prod; 2009 Sep;72(9):1631-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 70% ethanol extract of Soymida febrifuga was found to kill PANC-1 human pancreatic cancer cells preferentially under nutrition-deprived conditions at a concentration of 10 microg/mL.
  • In addition, the cytotoxic activity against colon 26-L5 carcinoma (colon 26-L5), B16-BL6 melanoma (B16-BL6), lung A549 adenocarcinoma (A549), cervix HeLa adenocarcinoma (HeLa), and HT-1080 fibrosarcoma (HT-1080) cell lines and their structure-activity relationship are discussed.

  • National BioResource Project. culture/stock collections - NBRP resources .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689125.001).
  • [ISSN] 1520-6025
  • [Journal-full-title] Journal of natural products
  • [ISO-abbreviation] J. Nat. Prod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Coumarins; 0 / Isoflavones; 0 / Stilbenes; 80168379AG / Doxorubicin
  •  go-up   go-down


18. Baker AC, Eltoum I, Curry RO, Stockard CR, Manne U, Grizzle WE, Chhieng D: Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. Arch Pathol Lab Med; 2006 Oct;130(10):1510-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix.
  • OBJECTIVE: To determine the expression of mucins in uterine cervical glandular lesions and whether mucin expression correlates with the nature and origin of the glandular lesions.
  • DESIGN: Antibodies to MUC1, MUC2, MUC4, and MUC5AC were applied on 52 cases including 14 endocervical adenocarcinomas (including 4 adenosquamous carcinomas), 9 endometrial carcinomas (8 endometrioid adenocarcinomas and 1 adenosquamous carcinoma), 8 adenocarcinoma in situ (AIS), 2 glandular dysplasias, 6 tubal metaplasias, 10 microglandular hyperplasias, and 3 normal endocervix.
  • Almost all endocervical AIS and carcinomas and all endometrial adenocarcinomas expressed MUC1; the exceptions were 2 cases of endocervical adenocarcinoma and 1 case of adenosquamous carcinoma of the endocervix.
  • MUC2 staining was noted in 25%, 40%, and 22% of AIS, endocervical adenocarcinomas, and endometrial adenocarcinomas, respectively.
  • About 38% of AIS, 75% of endocervical adenocarcinomas, and 44% of endometrial adenocarcinomas expressed MUC4.
  • Half of AIS, most of endocervical adenocarcinomas, and 22% of endometrial adenocarcinomas expressed MUC5AC.
  • These results suggest that mucin staining may potentially be helpful in differentiating various uterine cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Mucins / metabolism. Uterine Cervical Diseases / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090193.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / MUC4 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-4; 0 / Mucins
  •  go-up   go-down


19. Matsuura Y, Kawagoe T, Toki N, Hachisuga T, Kashimura M: [Uterine cervical cancer screening in Japan: today and future]. J UOEH; 2009 Jun 1;31(2):181-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uterine cervical cancer screening in Japan: today and future].
  • Despite the proven effectiveness of cytological uterine cervical cancer screening, the consultation rate for cancer screening in Japan is markedly low in comparison with other developed countries.
  • Although the mortality of this cancer has been steadily decreasing, it has been on the rise in the recent several years.
  • It is evident that human papillomavirus (HPV) is involved in the occurrence of uterine cervical cancer, and, because of changes in sexual awareness and the diversification of sexual behavior, the increase in the incidence of uterine cervical cancer, especially among young adults, has become a major social problem.
  • There is a false negative rate of about 10% in cytological uterine cervical cancer screening, seen mostly in cervical adenocarcinoma cases.
  • As there is a limit to the effectiveness of cancer screening by cytology alone, there is a movement in Japan to increase the accuracy of cytological screening by using liquid-based cytology (LBC) and adopting HPV testing.
  • There are various problems in cytological cancer screening, but the national and local governments, medical institutions, companies, and educational institutions must have an accurate understanding of the current situation and take an assertive approach in order to decrease the mortality rate of uterine cervical cancer.
  • [MeSH-major] Cytodiagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Japan / epidemiology. Papillomavirus Infections / diagnosis


20. Coupienne I, Piette J, Bontems S: How to monitor NF-kappaB activation after photodynamic therapy. Methods Mol Biol; 2010;635:79-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For several years, photodynamic therapy (PDT) has emerged as an attractive alternative approach for the treatment of different affections involving various forms of cancer and an increasing number of reports have highlighted the activation of the NF-kappaB following PDT treatment.
  • As a working model we will present results obtained from a 5-aminolevulinic acid-PDT treatment on cervix adenocarcinoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552341.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Photosensitizing Agents; 0 / Synaptotagmin I; 139874-52-5 / NF-kappaB inhibitor alpha; 88755TAZ87 / Aminolevulinic Acid; EC 1.13.12.- / Luciferases
  •  go-up   go-down


21. Yang YC, Lee ZY, Wu CC, Chen TC, Chang CL, Chen CP: CXCR4 expression is associated with pelvic lymph node metastasis in cervical adenocarcinoma. Int J Gynecol Cancer; 2007 May-Jun;17(3):676-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4 expression is associated with pelvic lymph node metastasis in cervical adenocarcinoma.
  • The aim of this study is to investigate the expression of CXCR4 receptor in cervical adenocarcinoma and related mechanisms involved in pelvic lymph node metastasis.
  • Immunohistochemistry was used to evaluate the expression of CXCR4 and the association of pelvic lymph node metastasis in archived tissue from clinical stage IB cervical adenocarcinomas (n = 37) and from benign specimens obtained at hysterectomy for other causes (n = 48).
  • The HeLa cell (cervical adenocarcinoma-derived cell) line that expresses CXCR4 was used to study the interaction between the CXCR4 receptor and stromal cell-derived factor 1alpha (SDF-1alpha).
  • We conclude CXCR4 expression is associated with cervical adenocarcinoma cell migration and proliferation, and primary cervical adenocarcinoma cells expressing CXCR4 are significantly more likely to metastasize to pelvic lymph nodes.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Metastasis. Receptors, CXCR4 / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504381.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Receptors, CXCR4; EC 2.7.11.1 / Oncogene Protein v-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


22. Schmidt D, Horn LC, Kommoss F: [Histopathology of squamous cell carcinoma and adenocarcinoma of the uterine cervix]. Pathologe; 2005 Jul;26(4):255-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathology of squamous cell carcinoma and adenocarcinoma of the uterine cervix].
  • [Transliterated title] Histopathologie des Plattenepithelkarzinoms und des Adenokarzinoms der Cervix uteri.
  • The introduction of a screening programme for carcinoma of the cervix uteri has lead to a reduction in the number of invasive carcinomas and to a relative increase in the frequency of preinvasive cervical lesions.
  • The most frequent type of invasive cancer of the cervix is squamous cell carcinoma.
  • Adenocarcinomas are much more infrequent.
  • Among the various forms of adenocarcinoma, the mucinous subtype is the most frequent, either as endocervical or interstinal subtype.
  • Great concern in daily diagnosis causes the adenoma malignum (minimal deviation adenocarcinoma), since this type of adenocarcinoma demonstrates only minor cytological atypia and greatly resembles the different types of endocervical glandular hyperplasia.A report on a cervical carcinoma should always include the typing and grading of the tumor.
  • Immunohistochemical stains are often useful to distinguish the various types of primary cervical cancer and to distinguish these from metastatic lesions.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Uterine Cervical Neoplasms / pathology


23. Sato H, Nanjo H, Tanaka H, Tanaka T: Arias-Stella reaction in an adenomyomatous polyp of the uterus. Acta Obstet Gynecol Scand; 2007;86(1):106-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 33-year-old Japanese woman, gravida 1, para 1, presented for an initial prenatal examination at 6-week gestation; ultrasound revealed a myoma-like solid mass in the cervical canal.
  • An abnormal Papanicolaou's smear (highly suspicious of adenocarcinoma) prompted the resection of this pedunculated polyp.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cervix Uteri / cytology. Pregnancy Complications, Neoplastic / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Pregnancy. Pregnancy Trimester, First. Vaginal Smears


24. Delotte J, Ferron G, Kuei TL, Mery E, Gladieff L, Querleu D: Laparoscopic management of an isolated ovarian metastasis on a transposed ovary in a patient treated for stage IB1 adenocarcinoma of the cervix. J Minim Invasive Gynecol; 2009 Jan-Feb;16(1):106-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of an isolated ovarian metastasis on a transposed ovary in a patient treated for stage IB1 adenocarcinoma of the cervix.
  • Transposition of the ovaries is performed frequently in young women with early-stage cervical cancer.
  • However, this must be balanced with the risks of ovarian metastases especially in patients with adenocarcinomas.
  • We report the first case of laparoscopic management of an isolated metastasis to a transposed ovary that occurred 2 years after primary laparoscopic treatment of a stage IB1 adenocarcinoma of the cervix.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy / methods. Lymph Node Excision. Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery. Ovariectomy / methods. Uterine Cervical Neoplasms / pathology


25. van Dijck JA, Doorduijn Y, Bulten JH, Verloop J, Massuger LF, Kiemeney BA: [Vaginal and cervical cancer due to diethylstilbestrol (DES); end epidemic]. Ned Tijdschr Geneeskd; 2009;153:A366
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vaginal and cervical cancer due to diethylstilbestrol (DES); end epidemic].
  • OBJECTIVE: To determine the current situation regarding the epidemic of clear cell adenocarcinoma of the vagina and the uterine cervix (CCAC) in relation to the exposure in utero to diethylstilbestrol (DES).
  • METHODS: Patients with CCAC of the uterine cervix or vagina born after 1946 and diagnosed in the period 1969-2005, were identified through the Nationwide network and registry of histo- and cytopathology in the Netherlands and from 2003 onwards through the Netherlands Cancer Registry.
  • For the patients who did not provide consent, only the date of diagnosis and age at diagnosis were known (n = 10).
  • Age at diagnosis varied from 8-54 years (mean: 28 years).
  • The mean age at diagnosis was 24 years for exposed patients compared to 32 years for non-exposed patients.
  • CONCLUSION: Since 2000, the incidence of CCAC of the vagina and cervix has decreased markedly compared to the situation in the 1980s and 1990 s.
  • [MeSH-major] Adenocarcinoma, Clear Cell / epidemiology. Diethylstilbestrol / adverse effects. Uterine Cervical Neoplasms / epidemiology. Vaginal Neoplasms / epidemiology


26. Vandecasteele K, De Neve W, De Gersem W, Delrue L, Paelinck L, Makar A, Fonteyne V, De Wagter C, Villeirs G, De Meerleer G: Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation. Strahlenther Onkol; 2009 Dec;185(12):799-807
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation.
  • PURPOSE: To report on the planning procedure, quality control, and clinical implementation of intensity-modulated arc therapy (IMAT) delivering a simultaneous integrated boost (SIB) in patients with primary irresectable cervix carcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Intensity-Modulated / methods. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cervix Uteri / radiation effects. Dose Fractionation. Female. Film Dosimetry. Humans. Image Processing, Computer-Assisted. Intestines / radiation effects. Lymphatic Irradiation. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Positron-Emission Tomography. Quality Control. Radiotherapy Dosage. Tomography, X-Ray Computed. Urinary Bladder / radiation effects

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1606-13 [10764420.001]
  • [Cites] Phys Med Biol. 2004 Jan 21;49(2):287-305 [15083672.001]
  • [Cites] Strahlenther Onkol. 2008 Sep;184(9):473-7 [19016026.001]
  • [Cites] Am J Obstet Gynecol. 2007 Nov;197(5):503.e1-6 [17980189.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002225 [16034873.001]
  • [Cites] Strahlenther Onkol. 2009 May;185(5):282-7 [19440666.001]
  • [Cites] J Nucl Med. 2005 Nov;46(11):1842-50 [16269598.001]
  • [Cites] Cancer Radiother. 2002 Nov;6 Suppl 1:32s-36s [12587381.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):933-9 [15936580.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1330-7 [11955746.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):794-806 [15465196.001]
  • [Cites] Strahlenther Onkol. 2007 Sep;183(9):487-9 [17762922.001]
  • [Cites] Radiother Oncol. 2003 Sep;68(3):217-26 [13129628.001]
  • [Cites] Radiother Oncol. 2005 Sep;76(3):340-53 [16099521.001]
  • [Cites] Radiat Oncol. 2006 May 04;1:13 [16722546.001]
  • [Cites] Radiother Oncol. 2007 May;83(2):148-55 [17531904.001]
  • [Cites] Gynecol Oncol. 1993 Jun;49(3):311-7 [8314532.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1371-88 [11728699.001]
  • [Cites] Radiother Oncol. 2007 Aug;84(2):156-63 [17692976.001]
  • [Cites] Gynecol Oncol. 2006 Sep;102(3):523-9 [16504274.001]
  • [Cites] Strahlenther Onkol. 2005 Jul;181(7):424-30 [15995835.001]
  • [Cites] Gynecol Oncol. 1994 Jul;54(1):68-75 [8020842.001]
  • [Cites] Semin Radiat Oncol. 2002 Jul;12(3):260-71 [12118391.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1019-32 [14575833.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183 Spec No 2:19-20 [18167001.001]
  • [Cites] Strahlenther Onkol. 2005 Aug;181(8):483-99 [16044216.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(1):47-9 [16550968.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):373-9 [10684713.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1062-70 [15752885.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):830-41 [15708263.001]
  • [Cites] Strahlenther Onkol. 2009 Mar;185(3):177-83 [19330295.001]
  • [Cites] Eur J Surg Oncol. 2008 May;34(5):569-75 [17531428.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):95-100 [1993635.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):261-6 [11516876.001]
  • [Cites] Gynecol Oncol. 2006 Aug;102(2):182-8 [16516281.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):343-53 [12798694.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):324-8 [10985888.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1257-80 [7713787.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2804-10 [17502627.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2006 Feb;18(1):38-45 [16477918.001]
  • [Cites] Med Phys. 1998 May;25(5):656-61 [9608475.001]
  • [Cites] Phys Med Biol. 2007 Jan 7;52(1):231-42 [17183138.001]
  • [Cites] Strahlenther Onkol. 2008 Nov;184(11):586-91 [19016017.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2002 Jun;14(3):203-12 [12109823.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1438-44 [17394944.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1604-12 [16198509.001]
  • [Cites] Cancer Treat Rev. 2003 Dec;29(6):471-88 [14585258.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):498-503 [17156969.001]
  • (PMID = 20013089.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. McLeod M, Harris R, Purdie G, Cormack D, Robson B, Sykes P, Crengle S, Iupati D, Walker N: Improving survival disparities in cervical cancer between Māori and non-Māori women in New Zealand: a national retrospective cohort study. Aust N Z J Public Health; 2010 Apr;34(2):193-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving survival disparities in cervical cancer between Māori and non-Māori women in New Zealand: a national retrospective cohort study.
  • OBJECTIVE: Māori women in New Zealand have higher incidence of and mortality from cervical cancer than non-Māori women, however limited research has examined differences in treatment and survival between these groups.
  • This study aims to determine if ethnic disparities in treatment and survival exist among a cohort of Māori and non-Māori women with cervical cancer.
  • METHODS: A retrospective cohort study of 1911 women (344 Māori and 1567 non-Māori) identified from the New Zealand Cancer Register with cervical cancer (adenocarcinoma, adenosquamous or squamous cell carcinoma) between 1 January 1996 and 31 December 2006.
  • RESULTS: Māori women with cervical cancer had a higher receipt of total hysterectomies, and similar receipt of radical hysterectomies and brachytherapy as primary treatment, compared to non-Māori women (age and stage adjusted).
  • Over the cohort period, Māori women had poorer cancer specific survival than non-Māori women (mortality hazard ratio (HR) 2.07, 95% confidence interval (CI): 1.63-2.62).
  • CONCLUSION: Māori continue to have higher incidence and mortality than non-Māori from cervical cancer although disparities are improving.
  • IMPLICATIONS: Primary prevention and early detection remain key interventions for addressing Māori needs and reducing inequalities in cervical cancer in New Zealand.
  • [MeSH-major] Carcinoma / ethnology. Carcinoma / mortality. European Continental Ancestry Group / statistics & numerical data. Healthcare Disparities / ethnology. Oceanic Ancestry Group / statistics & numerical data. Uterine Cervical Neoplasms / ethnology. Uterine Cervical Neoplasms / mortality


28. Kuo KT, Liang CW, Hsiao CH, Lin CH, Chen CA, Sheu BC, Lin MC: Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma. Mod Pathol; 2006 Dec;19(12):1570-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma.
  • Neuroendocrine carcinomas of the uterine cervix are rare tumors with early metastases, highly aggressive clinical behavior, and poor clinical outcome.
  • We have examined the expression of the standard CD44 (CD44s) by immunohistochemical stains in the paraffin-embedded cervical neoplasm tissue of 17 cases of primary cervical neuroendocrine carcinoma, 28 cases of cervical adenocarcinoma, and 50 cases of cervical squamous cell carcinoma.
  • Loss of CD44s expression was found in 16 of 17 neuroendocrine carcinomas, 14 of 28 adenocarcinomas, and three of 50 squamous cell carcinomas.
  • Loss of BRG-1 expression was observed in 12/16, 6/14, and 1/3 CD44s-negative neuroendocrine carcinomas, adenocarcinomas, and squamous cell carcinomas, respectively.
  • This study suggests that loss of the CD44s molecule may imply special biological behaviors of cervical neuroendocrine carcinomas, and loss of expression of BRG-1 may contribute to this.
  • [MeSH-major] Antigens, CD44 / metabolism. Carcinoma, Neuroendocrine / metabolism. Carcinoma, Squamous Cell / metabolism. DNA Helicases / metabolism. Down-Regulation. Nuclear Proteins / metabolism. Transcription Factors / metabolism. Uterine Cervical Neoplasms / metabolism


29. Vrdoljak E, Boraska Jelavic T, Saratlija-Novakovic Z, Hamm W: Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri. Eur J Gynaecol Oncol; 2005;26(6):602-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri.
  • The optimal treatment of women with locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri is still undefined.
  • We report a series of four consecutive patients with locally advanced adeno- or adenosquamous carcinomas of the uterine cervix (FIGO Stages IB-IIIB) treated by concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by one to four cycles of consolidation chemotherapy with the same drug combination.
  • Despite the low number of patients in this series we may conclude that concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy with the same drug combination is an efficacious treatment of patients with locally advanced adeno- or adenosquamous carcinomas of the cervix uteri.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / drug therapy. Uterine Cervical Neoplasms / drug therapy


30. Epstein E, Di Legge A, Måsbäck A, Lindqvist PG, Kannisto P, Testa AC: Sonographic characteristics of squamous cell cancer and adenocarcinoma of the uterine cervix. Ultrasound Obstet Gynecol; 2010 Oct;36(4):512-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic characteristics of squamous cell cancer and adenocarcinoma of the uterine cervix.
  • OBJECTIVE: The objective of this study was to describe the sonographic characteristics of squamous cell cancer (SCC) and adenocarcinoma (AC) of the cervix using transvaginal ultrasound.
  • METHODS: Women with early stage cervical cancer undergoing transvaginal ultrasound examination before surgery were prospectively included.
  • At pathological examination, 34 women had tumors confined to the cervix, three had parametrial invasion and three had vaginal invasion.
  • Color Doppler signals were found in all cases of AC and in 90% (18/20) of cases of SCC, compared with most normal cervical tissue in which virtually no detectable vascularization was found.
  • This knowledge should be useful in the clinical evaluation of cervical tumors.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Carcinoma, Squamous Cell / ultrasonography. Cervix Uteri / ultrasonography. Uterine Cervical Neoplasms / ultrasonography


31. Dunton CJ: Management of atypical glandular cells and adenocarcinoma in situ. Obstet Gynecol Clin North Am; 2008 Dec;35(4):623-32; ix
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of atypical glandular cells and adenocarcinoma in situ.
  • Glandular abnormalities of the cervix remain a difficult clinical problem.
  • It also discusses the diagnosis of associated endometrial lesions and the use of human papillomavirus DNA testing in the management of glandular lesions of the lower genital tract.
  • [MeSH-major] Adenocarcinoma / therapy. Cervical Intraepithelial Neoplasia / therapy. Pregnancy Complications, Neoplastic / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Cervix Uteri / cytology. Cervix Uteri / pathology. DNA, Viral / analysis. Female. Humans. Middle Aged. Papillomaviridae / isolation & purification. Papillomavirus Infections / complications. Papillomavirus Infections / pathology. Papillomavirus Infections / therapy. Postmenopause. Pregnancy. Vaginal Smears. Young Adult


32. Simon SK, Bolanca IK, Sentija K, Kukura V, Valetić J, Skrtić A: Vulvar Paget's disease--a case report. Coll Antropol; 2010 Jun;34(2):649-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vulvar Morbus Paget (MP) represents a rare intraepithelial adenocarcinoma.
  • Occasionally, single anaplastic Paget's cells can be found on the vulvar smears which make cytological diagnosis of the disease possible.
  • Accordingly, cytological diagnosis vulvar intraepithelial neoplasia (VIN III) with differential diagnosis of vulvar Paget's disease was made.
  • The pathological verification supported the diagnosis of MP and an immunohistochemistry panel confirmed type III of Paget's disease and an evaluation of bladder was suggested.
  • [MeSH-minor] Cervix Uteri / pathology. Female. Humans. Keratin-7 / analysis. Kidney Transplantation. Liver Transplantation. Middle Aged. Vaginal Smears. Vulva / pathology

  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698146.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Keratin-7
  •  go-up   go-down


33. Trávnícek Z, Starha P, Popa I, Vrzal R, Dvorák Z: Roscovitine-based CDK inhibitors acting as N-donor ligands in the platinum(II) oxalato complexes: preparation, characterization and in vitro cytotoxicity. Eur J Med Chem; 2010 Oct;45(10):4609-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro cytotoxic activity of the complexes against ovarian carcinoma (A2780), cisplatin resistant ovarian carcinoma (A2780cis), malignant melanoma (G-361), lung carcinoma (A549), cervix epitheloid carcinoma (HeLa), breast adenocarcinoma (MCF7) and osteosarcoma (HOS) human cancer cell lines was evaluated.
  • All the tested complexes exceeded the in vitro cytotoxicity of cisplatin and oxaliplatin against HeLa, A2780cis and, except for 2, also against HOS cancer cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20692737.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / Oxalates; 0 / Protein Kinase Inhibitors; 0 / Purines; 0 / roscovitine; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


34. Herbig ME, Weller K, Krauss U, Beck-Sickinger AG, Merkle HP, Zerbe O: Membrane surface-associated helices promote lipid interactions and cellular uptake of human calcitonin-derived cell penetrating peptides. Biophys J; 2005 Dec;89(6):4056-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, tighter binding to model membranes was associated with an increase in the in vitro uptake in human cervix epithelial adenocarcinoma cell line cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Pharmacol Sci. 2000 Mar;21(3):99-103 [10689363.001]
  • [Cites] Nucleic Acids Res. 1997 Jul 15;25(14):2730-6 [9207018.001]
  • [Cites] Trends Cell Biol. 2000 Jul;10(7):290-5 [10856932.001]
  • [Cites] Annu Rev Biochem. 2000;69:881-922 [10966478.001]
  • [Cites] FEBS Lett. 2000 Oct 6;482(3):265-8 [11024473.001]
  • [Cites] J Mol Biol. 2001 Jan 12;305(2):307-29 [11124908.001]
  • [Cites] Eur J Biochem. 2001 Mar;268(5):1304-14 [11231282.001]
  • [Cites] Biochemistry. 2001 Mar 13;40(10):3141-9 [11258929.001]
  • [Cites] FEBS Lett. 2001 May 18;497(1):39-44 [11376659.001]
  • [Cites] Biophys J. 2001 Dec;81(6):3332-8 [11720996.001]
  • [Cites] J Pept Sci. 1999 Apr;5(4):185-94 [10323198.001]
  • [Cites] FEBS Lett. 1999 Apr 23;449(2-3):221-4 [10338136.001]
  • [Cites] Arch Oral Biol. 1999 Jun;44(6):519-23 [10401530.001]
  • [Cites] Biochim Biophys Acta. 2004 Nov 3;1666(1-2):40-50 [15519307.001]
  • [Cites] Biochim Biophys Acta. 2005 Jun 30;1712(2):197-211 [15919050.001]
  • [Cites] Q Rev Biophys. 2004 May;37(2):147-95 [15997889.001]
  • [Cites] Nat Biotechnol. 2001 Dec;19(12):1173-6 [11731788.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):585-90 [12411431.001]
  • [Cites] Curr Protein Pept Sci. 2003 Apr;4(2):125-32 [12678851.001]
  • [Cites] Endocrinol Metab Clin North Am. 2003 Mar;32(1):273-84 [12699303.001]
  • [Cites] Nucleic Acids Res. 2003 Jun 1;31(11):2717-24 [12771197.001]
  • [Cites] Mol Ther. 2003 Jul;8(1):143-50 [12842437.001]
  • [Cites] Eur J Biochem. 2003 Jul;270(14):3055-63 [12846839.001]
  • [Cites] J Mol Recognit. 2003 Sep-Oct;16(5):227-33 [14523933.001]
  • [Cites] J Mol Recognit. 2003 Sep-Oct;16(5):280-7 [14523941.001]
  • [Cites] Pharm Res. 2003 Nov;20(11):1812-9 [14661926.001]
  • [Cites] Pharm Res. 2004 Jan;21(1):33-42 [14984255.001]
  • [Cites] Nat Med. 2004 Mar;10(3):310-5 [14770178.001]
  • [Cites] Eur J Biochem. 2004 Mar;271(6):1187-97 [15009197.001]
  • [Cites] Pharm Res. 2004 Mar;21(3):389-93 [15070086.001]
  • [Cites] FEBS Lett. 2004 Jun 4;567(2-3):265-9 [15178334.001]
  • [Cites] Pharm Res. 2004 Jul;21(7):1248-56 [15290867.001]
  • [Cites] Eur J Pharm Biopharm. 2004 Sep;58(2):209-23 [15296950.001]
  • [Cites] Biochem J. 2004 Sep 15;382(Pt 3):945-56 [15193145.001]
  • [Cites] Biochemistry. 2004 Oct 5;43(39):12459-68 [15449935.001]
  • [Cites] Biochem Biophys Res Commun. 1980 Jul 16;95(1):1-6 [7417242.001]
  • [Cites] Biochim Biophys Acta. 1981 Apr 6;642(2):296-312 [6269613.001]
  • [Cites] J Immunol Methods. 1983 May 27;60(1-2):115-24 [6406600.001]
  • [Cites] Biochim Biophys Acta. 1986 Jun 13;858(1):161-8 [3707960.001]
  • [Cites] J Immunol Methods. 1987 Jul 16;101(1):119-25 [3112235.001]
  • [Cites] J Pharm Biomed Anal. 1990;8(8-12):761-9 [2100620.001]
  • [Cites] Biochemistry. 1992 Dec 15;31(49):12416-23 [1463728.001]
  • [Cites] Biophys J. 1997 Aug;73(2):831-8 [9251799.001]
  • [Cites] J Mol Biol. 1997 Oct 17;273(1):283-98 [9367762.001]
  • [Cites] Trends Cell Biol. 1998 Feb;8(2):84-7 [9695814.001]
  • [Cites] Proteins. 1998 Aug 15;32(3):314-23 [9715908.001]
  • [Cites] Biochim Biophys Acta. 1998 Nov 10;1376(3):339-52 [9804985.001]
  • [Cites] Biochemistry. 1998 Nov 24;37(47):16582-90 [9843425.001]
  • [Cites] J Immunol Methods. 1993 Jun 4;162(1):1-7 [8509646.001]
  • [Cites] Biochemistry. 1994 Sep 6;33(35):10681-92 [8075068.001]
  • [Cites] Biochemistry. 1994 Nov 8;33(44):12990-7 [7947703.001]
  • [Cites] J Biol Chem. 1996 Jul 26;271(30):18188-93 [8663410.001]
  • [Cites] Biochemistry. 1996 Sep 3;35(35):11361-8 [8784191.001]
  • [Cites] Biochemistry. 1996 Sep 24;35(38):12612-22 [8823199.001]
  • [Cites] Curr Opin Neurobiol. 1996 Oct;6(5):629-34 [8937827.001]
  • [Cites] Eur J Biochem. 1996 Dec 1;242(2):372-86 [8973656.001]
  • [Cites] Biochemistry. 1997 Jul 1;36(26):8153-63 [9201964.001]
  • [Cites] J Neurosci Methods. 2000 Mar 15;96(2):147-52 [10720679.001]
  • (PMID = 16183886.001).
  • [ISSN] 0006-3495
  • [Journal-full-title] Biophysical journal
  • [ISO-abbreviation] Biophys. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0 / Membrane Lipids; 0 / Peptide Fragments; 0 / calcitonin (9-32), human; 9007-12-9 / Calcitonin
  • [Other-IDs] NLM/ PMC1366971
  •  go-up   go-down


35. Hovland S, Muller S, Skomedal H, Mints M, Bergström J, Wallin KL, Karlsen F, Johansson B, Andersson S: E6/E7 mRNA expression analysis: a test for the objective assessment of cervical adenocarcinoma in clinical prognostic procedure. Int J Oncol; 2010 Jun;36(6):1533-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E6/E7 mRNA expression analysis: a test for the objective assessment of cervical adenocarcinoma in clinical prognostic procedure.
  • Detection of E6/E7 mRNA expression using the real-time nucleic acid sequence-based amplification assay (NASBA) PreTect HPV-Proofer was compared with results of human papillomavirus (HPV) DNA detection in 98 paraffin-embedded samples from patients with cervical adenocarcinoma.
  • Further studies may reveal whether the clinical performance of the E6/E7 mRNA assay will be of prognostic value in management of cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. DNA, Viral / analysis. Gene Expression Profiling / methods. Oncogene Proteins, Viral / analysis. RNA, Viral / analysis. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] DNA-Binding Proteins / analysis. DNA-Binding Proteins / genetics. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis / methods. Papillomavirus E7 Proteins / analysis. Papillomavirus E7 Proteins / genetics. Papillomavirus Infections / diagnosis. Papillomavirus Infections / virology. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Prognosis. RNA, Messenger / analysis. Repressor Proteins / analysis. Repressor Proteins / genetics. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428778.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / E6 protein, Human papillomavirus type 16; 0 / E6 protein, Human papillomavirus type 18; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / RNA, Messenger; 0 / RNA, Viral; 0 / Repressor Proteins
  •  go-up   go-down


36. Ghosh SB, Tempe A: Retroperitoneal adenocarcinoma of unknown origin presenting as a rare cause of obstructed labor. Arch Gynecol Obstet; 2009 Mar;279(3):427-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal adenocarcinoma of unknown origin presenting as a rare cause of obstructed labor.
  • BACKGROUND: Metastatic retroperitoneal adenocarcinoma presenting as obstructed labor is extremely rare.
  • A palpable retroperitoneal mass was found behind the gravid uterus and cervix after delivery of a live baby during emergency cesarean section.
  • A diagnosis of retroperitoneal adenocarcinoma with an unknown primary was made based on histopathology and a negative workup for the possible primary sites.
  • [MeSH-major] Adenocarcinoma / complications. Dystocia / etiology. Pregnancy Complications, Neoplastic / pathology. Retroperitoneal Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665376.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Chajon E, Dumas I, Touleimat M, Magné N, Coulot J, Verstraet R, Lefkopoulos D, Haie-Meder C: Inverse planning approach for 3-D MRI-based pulse-dose rate intracavitary brachytherapy in cervix cancer. Int J Radiat Oncol Biol Phys; 2007 Nov 1;69(3):955-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverse planning approach for 3-D MRI-based pulse-dose rate intracavitary brachytherapy in cervix cancer.
  • PURPOSE: The purpose of this study was to evaluate the inverse planning simulated annealing (IPSA) software for the optimization of dose distribution in patients with cervix carcinoma treated with MRI-based pulsed-dose rate intracavitary brachytherapy.
  • [MeSH-major] Algorithms. Brachytherapy / methods. Software. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Carcinoma, Small Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Magnetic Resonance Imaging / methods. Radiotherapy Planning, Computer-Assisted / methods. Rectum / radiation effects. Urinary Bladder / radiation effects

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889277.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. González-Bosquet E, Suñol M, Morante D, Gomez Latre M, Callejo J, Lailla JM: Villoglandular papillary adenocarcinoma of the uterine cervix: a case report and literature review. Eur J Gynaecol Oncol; 2009;30(2):211-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix: a case report and literature review.
  • Villoglandular papillary adenocarcinoma is an infrequent form of well differentiated cervical papillary adenocarcinoma that has recently been described.
  • It usually affects young women and is distinguished from other adenocarcinomas by its generally good prognosis, since it infrequently invades the lymphovascular space.
  • We present a case of villoglandular papillary adenocarcinoma in a 28-year-old woman presenting risk factors for developing it: use of oral contraceptives, tobacco use, and infection with human papillomavirus types 16 and 33.
  • The presentation of this case provides an opportunity to review the literature on the diagnosis and treatment of villoglandular papillary adenocarcinoma, and the factors that may influence the prognosis of women diagnosed with this histological type of cervical cancer.
  • [MeSH-major] Adenocarcinoma, Papillary. Uterine Cervical Neoplasms


39. Hagiwara T, Kaku T, Kobayashi H, Hirakawa T, Nakano H: Clinico-cytological study of uterine papillary serous carcinoma. Cytopathology; 2005 Jun;16(3):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-cytological study of uterine papillary serous carcinoma.
  • OBJECTIVE: The aim of this study was to determine whether or not we could distinguish uterine papillary serous carcinoma (UPSC) from other types of endometrial cancer by cytology.
  • METHODS: We examined the cytological findings of the endometrium from five cases with UPSC and compared them with 10 cases with endometrioid adenocarcinoma, grade 1 (G1).
  • Cytological samples from the cervix and ascites of the patients with UPSC were also reviewed.
  • The findings of the nuclei and nucleoli in the cervical and peritoneal fluid cytology closely resembled those in endometrial smears.
  • The features of the cervical smears and peritoneal fluid cytology were different from those of endometrial cytology regarding clear background and small clusters of cells.
  • CONCLUSION: As the endometrial cytology findings accurately suggested the histological diagnosis of UPSC, the diagnosis of UPSC was confirmed in this study by endometrial cytology.
  • The cytological diagnosis of UPSC should be based on the findings of tumour diathesis, psammoma bodies and papillary clusters composed of tumour cells with enlarged nuclei and numerous nucleoli.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924607.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Hamer OW, Flint J, Ryan CF, Manos D, Müller NL: Mucoid impaction secondary to mucin-producing metastatic adenocarcinoma of the cervix. Br J Radiol; 2008 Aug;81(968):e201-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoid impaction secondary to mucin-producing metastatic adenocarcinoma of the cervix.
  • Here, we describe an uncommon case of endobronchial metastasis of adenocarcinoma of the cervix causing mucoid impaction owing to mucous production by the tumour cells.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Bronchial Neoplasms / secondary. Uterine Cervical Neoplasms


41. Ivanov S, Tiufekchieva E: [Modern treatment of early-stage cervical cancer]. Akush Ginekol (Sofiia); 2006;45(7):3-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modern treatment of early-stage cervical cancer].
  • AIM: In our study we tried to summerise our and foreign experience in the area of early stages of cervical cancer treatment MATERIAL AND METHODS: We examined 500 patients with early stage cervical cancer for 10 years period (1996-2006).
  • RESULTS: We analised the following important factors when treating the early stages cervical cancers: the histopathology type of tumour, the type of the conisation, the number of the tissue sections, the resection line numbers, the LVSI and the desire of the patients to preserve fertility.
  • In stage IB cervical cancer we used the best treatment choice: radical hysterectomy with pelvic lymph node dissection.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Cervix Uteri / surgery. Uterine Cervical Neoplasms / surgery


42. Nishida M, Nasu K, Takai N, Miyakawa I, Kashima K: Adenoid cystic carcinoma of the uterine cervix. Int J Clin Oncol; 2005 Jun;10(3):198-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the uterine cervix.
  • Adenoid cystic carcinoma of the uterine cervix is a rare and peculiar variant of adenocarcinoma.
  • This tumor represents 3% of all primary cervical adenocarcinomas, and it is locally aggressive and capable of metastasis to other organs even in its early stage.
  • Generally, radiotherapy and chemotherapy are chosen as the first treatment, because this cancer is seen most commonly in the elderly.
  • [MeSH-major] Carcinoma, Adenoid Cystic / radiotherapy. Uterine Cervical Neoplasms / radiotherapy


43. Fadare O, Zheng W: Well-differentiated papillary villoglandular adenocarcinoma of the uterine cervix with a focal high-grade component: is there a need for reassessment? Virchows Arch; 2005 Nov;447(5):883-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated papillary villoglandular adenocarcinoma of the uterine cervix with a focal high-grade component: is there a need for reassessment?
  • Well-differentiated villoglandular adenocarcinoma of the uterine cervix is characterized by an exophytic growth pattern with variably sized papillae that are lined by stratified columnar cells with no more than moderate cytologic atypia.
  • The case described herein is an otherwise prototypical well-differentiated villoglandular adenocarcinoma but which was associated with a 4.9-mm focus of poorly differentiated carcinoma at its invasive edge.
  • Our case suggests that well-differentiated villoglandular adenocarcinoma is not a diagnosis that should be unequivocally rendered on a small biopsy since other components may be present and the patients may be undertreated.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Chorionic Villi / pathology. Uterine Cervical Neoplasms / pathology


44. Meng YH, Li S, Hu T, Ma D, Lu YP, Wang H: [Clinical analysis of 132 cases of cervical adenosquamous carcinoma and cervical adenocarcinoma]. Chin J Cancer; 2010 Jan;29(1):15-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 132 cases of cervical adenosquamous carcinoma and cervical adenocarcinoma].
  • BACKGROUND AND OBJECTIVE: The incidence of cervical adenosquamous carcinoma is relatively low.
  • This study was to analyze the clinicopathologic characteristics and prognostic factors of cervical adenosquamous carcinoma.
  • METHODS: Clinical data of 44 cervical adenosquamous carcinoma patients and 88 cervical adenocarcinoma patients(control), treated from January 2002 to December 2007, were analyzed using Chi-square test, Kaplan-Meier method, log-rank test, and Cox regression model.
  • RESULTS: The proportion of large tumors (maximal diameter > 4 cm) was significantly higher in cervical adenosquamous carcinoma group than in cervical adenocarcinoma group (47.7% vs. 28.4%, P<0.05); the proportion of poorly differentiated tumors was significantly higher in cervical adenosquamous carcinoma group than in cervical adenocarcinoma group (56.8% vs. 30.7%, P<0.05).
  • CONCLUSIONS: Cervical adenosquamous carcinoma is characterized by large tumor size and poor differentiation.
  • There is no difference in prognosis between cervical adenosquamous carcinoma and cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology


45. Zannoni GF, Vellone VG, Carbone A: Morphological effects of radiochemotherapy on cervical carcinoma: a morphological study of 50 cases of hysterectomy specimens after neoadjuvant treatment. Int J Gynecol Pathol; 2008 Apr;27(2):274-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological effects of radiochemotherapy on cervical carcinoma: a morphological study of 50 cases of hysterectomy specimens after neoadjuvant treatment.
  • The introduction of radiochemotherapy for treatment of advanced cervical cancers represents a new chapter in surgical pathology.
  • The study group included 50 women with a histological diagnosis of advanced cervical carcinoma (43 squamous, 3 adenosquamous, 2 adenocarcinoma, 1 glassy cell, and 1 undifferentiated; International Federation of Gynecology and Obstetrics stage Ib-III) receiving a platinum-based chemotherapy concomitant with external beam radiotherapy before radical surgery.
  • In most cases, morphological criteria are sufficient to make a diagnosis, but sometimes, the use of immunohistochemistry (keratins and CD68) is a mandatory method to reveal the nature of the lesion.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / pathology. Hysterectomy. Neoadjuvant Therapy / methods. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Biomarkers, Tumor / metabolism. Cervix Uteri / drug effects. Cervix Uteri / radiation effects. Cervix Uteri / surgery. Combined Modality Therapy. Female. Humans. Keratins / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317212.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 68238-35-7 / Keratins
  •  go-up   go-down


46. Ikeda O, Mizukami N, Murata Y, Arakawa A, Katabuchi H, Okamoto H, Yasunaga T, Tsunawaki A, Yamashita Y: Randomized comparison of intra-arterial chemotherapy versus intra-arterial chemotherapy and gelfoam embolization for treatment of advanced cervical carcinoma. Cardiovasc Intervent Radiol; 2005 Nov-Dec;28(6):736-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of intra-arterial chemotherapy versus intra-arterial chemotherapy and gelfoam embolization for treatment of advanced cervical carcinoma.
  • PURPOSE: We evaluated the effects of intra-arterial infusion therapy by comparing the results obtained with a combination of intra-arterial anticancer drugs with and without transcatheter arterial embolization (TAE) in patients with cervical cancer.
  • METHODS: Between April 1999 and March 2003, intra-arterial therapy was administered to 45 patients (mean age 49 years) with cervical cancer.
  • Of these, 18 had stage IIb , 4 had stage IIIa, 19 had stage IIIb, and 4 had stage IVb cancer; the histopathologic types were squamous cell carcinoma (n = 35), adenocarcinoma (n = 8), and adenosquamous carcinoma (n = 2).
  • [MeSH-major] Carcinoma / therapy. Drug Therapy, Combination. Embolization, Therapeutic / methods. Gelatin Sponge, Absorbable / therapeutic use. Hemostatics / therapeutic use. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cervix Uteri / pathology. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Infusions, Intra-Arterial / methods. Magnetic Resonance Imaging / methods. Middle Aged. Mitomycin / adverse effects. Mitomycin / therapeutic use. Treatment Outcome


47. Swartz RJ, West LA, Boiko I, Malpica A, Guillaud M, Macaulay C, Follen M, Atkinson EN, Cox DD: Classification using the cumulative log-odds in the quantitative pathologic diagnosis of adenocarcinoma of the cervix. Gynecol Oncol; 2005 Dec;99(3 Suppl 1):S24-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification using the cumulative log-odds in the quantitative pathologic diagnosis of adenocarcinoma of the cervix.
  • The method was tested using data from cervical adenocarcinomas, adenocarcinoma in situ, and normal columnar tissue.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Logistic Models. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


48. Martin A, Torrent A: Laparoscopic nerve-sparing radical trachelectomy: surgical technique and outcome. J Minim Invasive Gynecol; 2010 Jan-Feb;17(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY OBJECTIVE: To assess the feasibility of the laparoscopic approach in fertility-preserving and radical surgery of cervical cancer in young patients.
  • SETTING: Hospital Son Llatzer, Palma de Mallorca, Spain.
  • PATIENTS: Nine women with early cervical cancer.
  • MEASUREMENTS AND MAIN RESULTS: Data for 9 consecutive women undergoing laparoscopic nerve-sparing radical trachelectomy because of FIGO IA2 (n=2) or FIGO IB1 (n=7) infiltrating cervical carcinoma of the squamous type (n=6) or adenocarcinoma (n=3) were analyzed.
  • CONCLUSIONS: Laparoscopic nerve-sparring radical trachelectomy may be an alternative in fertility-preserving surgery for cervical cancer in centers in which specialization in radical vaginal surgery is lacking.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Cervix Uteri / surgery. Laparoscopy / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AAGL. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20129330.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Koo YJ, Lee JE, Hong SR, Kwon YS: Co-occurrence of an adenoma malignum and an endocervical-type adenocarcinoma of the uterine cervix in a woman with Peutz-Jeghers syndrome. J Gynecol Oncol; 2010 Sep;21(3):203-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-occurrence of an adenoma malignum and an endocervical-type adenocarcinoma of the uterine cervix in a woman with Peutz-Jeghers syndrome.
  • We report a rare co-occurrence of an adenoma malignum and an adenocarcinoma in a 30-year-old woman with Peutz-Jeghers syndrome.
  • A pelvic examination and an MRI revealed the co-occurrence of a 4×5 cm protruding adenocarcinoma of FIGO stage Ib2 based on a punch biopsy and a 4.5×5.7 cm multilocular cystic mass above the solid cancer.
  • Pathologic findings were consistent with adenocarcinoma (40%) and adenoma malignum (60%) confined to the cervix.
  • This study will contribute to defining the best diagnosis and treatment for these rare complicating tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20922146.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2948231
  • [Keywords] NOTNLM ; Adenocarcinoma / Adenoma malignum / Peutz-Jeghers syndrome
  •  go-up   go-down


50. Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM: A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev; 2008 Apr;222:316-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
  • To date, none of these cancer immunotherapies have been approved by the Food and Drug Administration for use in humans.
  • A significant problem is that the vast majority of such clinical trials are carried out in patients with advanced or metastatic cancer.
  • Recently, we and others have experimented with administering therapeutic cancer vaccines in the preventive setting.
  • These studies have demonstrated that early vaccination is extremely effective in eliciting an anti-tumor immune response that leads to unprecedented improvements in the survival of mice that spontaneously develop cancer.
  • Certain human cancers, notably prostate adenocarcinoma and cervical cancer, can currently be detected at very early stages of carcinogenesis.
  • The ability to immunize patients at the very earliest stages of carcinogenesis, when they have fully competent immune systems, has the potential to cause a paradigm shift in how therapeutic cancer vaccines are tested and used clinically.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Immunotherapy / methods. Neoplasms / immunology

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364011.001).
  • [ISSN] 1600-065X
  • [Journal-full-title] Immunological reviews
  • [ISO-abbreviation] Immunol. Rev.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / T32 GM 067587
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Papillomavirus Vaccines; 0 / Viral Vaccines
  • [Number-of-references] 90
  •  go-up   go-down


51. Muller S, Flores-Staino C, Skyldberg B, Hellström AC, Johansson B, Hagmar B, Wallin KL, Andersson S: Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma. Int J Oncol; 2008 Feb;32(2):333-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma.
  • A total of 101 primary cervical adenocarcinomas were analyzed for the presence of p16INK4a and MIB-1 expression in correlation with the presence of 'high-risk' types of human papillomavirus (HR-HPV) and clinical outcome.
  • We found that adenocarcinoma grading showed a significant negative correlation to p16INK4a levels (p=0.001): i.e. we found less intense p16 staining in poorly differentiated tumors than in more highly differentiated tumors as well as a highly significant correlation between HPV infection and higher levels of p16INK4a staining (p=0.00), which was similar for different HPV-types.
  • Higher MIB-1 levels were seen in tumors with a lower grade and higher stage at diagnosis.
  • MIB-1 may be a helpful marker in grading adenocarcinoma: a high level of expression of MIB-1 indicates a low grade of tumor, whereas high expression of p16INK4a indicates a highly differentiated of the tumor.
  • Thus, immunostaining for p16INK4a appears to be a useful diagnostic tool for cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / virology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Ki-67 Antigen / biosynthesis. Papillomaviridae / metabolism. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202755.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen
  •  go-up   go-down


52. Lai HC, Lin YW, Huang RL, Chung MT, Wang HC, Liao YP, Su PH, Liu YL, Yu MH: Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer; 2010 Sep 15;116(18):4266-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse.
  • BACKGROUND: DNA methylation may be used a potential biomarker for detecting cervical cancer.
  • The authors of this report used quantitative methylation analysis of 4 genes in a full spectrum of cervical lesions to test its potential clinical application.
  • METHODS: This hospital-based, retrospective, case-control study was conducted in 185 patients and included patients who had a normal uterine cervix (n = 53), cervical intraepithelial neoplasm type 1 (CIN1) (n = 37), CIN2 (n = 22), CIN3 (n = 24), carcinoma in situ (CIS) (n = 22), squamous cell carcinoma (SCC, n = 20), and adenocarcinoma (AC) (n = 7).
  • RESULTS: The PMRs of the 4 genes were significantly higher in CIN3 and worse (CIN3+) lesions than the PMRs in specimens of normal cervix and CIN1 or CIN2 (P < .001).
  • CONCLUSIONS: The current results indicated that quantitative PCR-based testing for DNA methylation of 4 genes holds great promise for cervical cancer screening and warrants further population-based studies using standardized DNA methylation testing.
  • [MeSH-major] Biomarkers / analysis. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / genetics. DNA Methylation. Polymerase Chain Reaction / methods

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • (PMID = 20564139.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


53. Liu MT, Hsu JC, Liu WS, Wang AY, Huang WT, Chang TH, Pi CP, Huang CY, Huang CC, Chou PH, Chen TH: Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy. Eur J Cancer Care (Engl); 2008 Mar;17(2):174-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy.
  • The purpose of this study is to investigate the clinical and histological features that may affect the survival of the patients and to evaluate the impact of post-operative adjuvant therapy on the outcomes of patients with stage IB and IIA carcinoma of the cervix.
  • From August 1998 to January 2005, 140 patients with International Federation of Gynecology and Obstetrics stage IB and IIA cervical cancer were treated with radical hysterectomy and post-operative pelvic radiation therapy with or without chemotherapy.
  • One hundred and eleven patients had histology of squamous cell carcinoma, 12 patients has adenocarcinoma and 17 patients had other histologic types.
  • For patients with high-risk early stage cervical cancer who underwent a radical hysterectomy and pelvic lymphadenectomy, adjuvant chemoradiotherapy resulted in better survival than radiotherapy alone.
  • [MeSH-major] Hysterectomy. Uterine Cervical Neoplasms / therapy


54. Nagar YS, Shah N, Rawat S, Kataria T: Intracranial metastases from adenocarcinoma of cervix: a case report. Int J Gynecol Cancer; 2005 May-Jun;15(3):561-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial metastases from adenocarcinoma of cervix: a case report.
  • Carcinoma of cervix usually spreads contiguously to the adjacent organs, by lymphatics to the pelvic and para-aortic lymph nodes and by hematogenous route to distant organs.
  • We report here a rare case of a 72-year-old woman with carcinoma of cervix, FIGO stage IIA, who developed metastases to the brain.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Uterine Cervical Neoplasms / pathology


55. Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P, National Cancer Institute Organ Dysfunction Working Group: Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res; 2007 Jun 15;13(12):3660-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.
  • EXPERIMENTAL DESIGN: Sixty adult cancer patients with variable hepatic function received i.v. oxaliplatin ranging from 60 to 130 mg/m(2) every 3 weeks.
  • Two of 56 assessable patients with a diagnosis of laryngeal carcinoma and cervical adenocarcinoma experienced partial responses lasting 3 and 5.5 months.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575231.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01CA062502; United States / NCI NIH HHS / CA / U01CA069855; United States / NCI NIH HHS / CA / U01CA03330; United States / NCI NIH HHS / CA / U01CA076642; United States / NCRR NIH HHS / RR / M01RR00080; United States / NCI NIH HHS / CA / U01CA033572; United States / NCRR NIH HHS / RR / RR00056; United States / NCI NIH HHS / CA / U01CA069853; United States / NCI NIH HHS / CA / U01CA069856; United States / NCI NIH HHS / CA / U01 CA062491; United States / NCI NIH HHS / CA / U01CA062505; United States / NCI NIH HHS / CA / U01CA062491
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


56. Piketty M, Barranger E, Najat M, François P, Daraï E: Ovarian recurrence after radical trachelectomy for adenocarcinoma of the cervix. Am J Obstet Gynecol; 2005 Oct;193(4):1382-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian recurrence after radical trachelectomy for adenocarcinoma of the cervix.
  • Radical trachelectomy is an effective fertility-sparing treatment for women with early-stage cervical cancer.
  • We describe the first reported ovarian recurrence after radical trachelectomy for stage IB1 adenocarcinoma cervical cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Cervix Uteri / surgery. Neoplasms, Second Primary. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery. Uterus / surgery


57. Caceres A, Mourton SM, Bochner BH, Gerst SR, Liu L, Alektiar KM, Kardos SV, Barakat RR, Boland PJ, Chi DS: Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended pelvic resections for recurrent uterine and cervical cancer: out-of-the-box surgery.
  • Patients with recurrent uterine and cervical cancer have poor prognoses.
  • The objective of this study was to analyze the outcomes of patients with recurrent uterine and cervical cancer who had undergone attempted curative resection of pelvic bone, sidewall muscle, major blood vessels, and/or nerves.
  • We reviewed the records of all 14 patients with recurrent uterine and cervical cancer who had extended pelvic resections at our institution between June 2000 and November 2006.
  • Primary sites of disease were the uterus (11 patients) and cervix (3 patients).
  • Tumor histology was as follows: adenocarcinoma, seven; squamous cell carcinoma, three; leiomyosarcoma, three; and adenosarcoma, one.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Pelvic Exenteration. Uterine Cervical Neoplasms / surgery


58. Altaf FJ: Cervical cancer screening with pattern of pap smear. Review of multicenter studies. Saudi Med J; 2006 Oct;27(10):1498-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical cancer screening with pattern of pap smear. Review of multicenter studies.
  • OBJECTIVE: To estimate the frequency of abnormal cervical smears and to compare the findings with earlier reported data from Saudi Arabia.
  • The malignant categories were squamous cell carcinoma (0.08%), adenocarcinoma of cervix in situ (0.02%) and invasive (0.04%).
  • Unified national programs for diagnosing cervical precancerous lesions should be established covering different region of the Kingdom to evaluate the magnitude of the problem.
  • [MeSH-major] Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / epidemiology. Vaginal Smears / trends


59. Saurine T, Danieletto S, Prabhala G, Russell P: Benign mucinous ovarian tumour with areas resembling microglandular hyperplasia of the cervix. Pathology; 2006 Feb;38(1):87-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign mucinous ovarian tumour with areas resembling microglandular hyperplasia of the cervix.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Hyperplasia. Mitosis. Progesterone / physiology


60. Xu Y, Ge R, Du J, Xin H, Yi T, Sheng J, Wang Y, Ling C: Corosolic acid induces apoptosis through mitochondrial pathway and caspase activation in human cervix adenocarcinoma HeLa cells. Cancer Lett; 2009 Nov 1;284(2):229-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corosolic acid induces apoptosis through mitochondrial pathway and caspase activation in human cervix adenocarcinoma HeLa cells.
  • We investigated the response of human cervix adenocarcinoma HeLa cells to Corosolic acid (CRA) treatment.
  • Taken together, we believe that CRA could have strong potentials for clinical application in treating human cervix adenocarcinoma and improving cancer chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents, Phytogenic / pharmacology. Caspases / physiology. Mitochondria / drug effects. Neoplasm Proteins / physiology. Triterpenes / pharmacology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ireland Ltd.
  • (PMID = 19457606.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BAX protein, human; 0 / Drugs, Chinese Herbal; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Triterpenes; 0 / bcl-2-Associated X Protein; 4547-24-4 / corosolic acid; EC 3.4.22.- / Caspases
  •  go-up   go-down


61. Schwendinger V, Müller-Holzner E, Zeimet AG, Marth C: Sentinel node detection with the blue dye technique in early cervical cancer. Eur J Gynaecol Oncol; 2006;27(4):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node detection with the blue dye technique in early cervical cancer.
  • OBJECTIVE: The aim of this study was to investigate the feasibility of sentinel node detection with the blue dye technique in early cervical cancer.
  • METHODS: In a retrospective study conducted between January 2000 and February 2005, 47 women with early cervical cancer (6 patients FIGO Stage I A, 38 patients FIGO Stage I B, 2 patients FIGO Stage II A, 1 patient FIGO Stage II B) who underwent class II-III radical hysterectomy with pelvic lymphadenectomy were identified.
  • Prior to surgery 1 ml of blue dye (lymphazurin 1%) was injected into the four quadrants of the cervix.
  • Our detection rate and sensitivity rate using the blue dye technique in cervical cancer are comparable to those in previously published data.
  • [MeSH-major] Lymph Nodes / pathology. Rosaniline Dyes. Sentinel Lymph Node Biopsy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Feasibility Studies. Female. Humans. Hysterectomy. Immunoenzyme Techniques. Lymph Node Excision. Middle Aged. Neoplasm Staging. Sensitivity and Specificity


62. Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest; 2008 Dec;118(12):3930-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We identified monocarboxylate transporter 1 (MCT1) as the prominent path for lactate uptake by a human cervix squamous carcinoma cell line that preferentially utilized lactate for oxidative metabolism.
  • A similar switch from lactate-fueled respiration to glycolysis by oxygenated tumor cells in both a mouse model of lung carcinoma and xenotransplanted human colorectal adenocarcinoma cells was observed after administration of CHC.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. OXYGEN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Med Today. 2000 Jan;6(1):15-9 [10637570.001]
  • [Cites] J Biol Chem. 2006 Apr 7;281(14):9030-7 [16452478.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):916-21 [10706105.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Apr;278(4):E571-9 [10751188.001]
  • [Cites] Biochem J. 2000 Aug 15;350 Pt 1:219-27 [10926847.001]
  • [Cites] J Physiol. 2000 Dec 1;529 Pt 2:285-93 [11101640.001]
  • [Cites] Neuroreport. 2001 Mar 26;12(4):761-5 [11277580.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):349-53 [11567808.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):840-8 [11699496.001]
  • [Cites] Novartis Found Symp. 2001;240:251-60; discussion 260-4 [11727934.001]
  • [Cites] FASEB J. 2002 Dec;16(14):1979-81 [12397083.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):617-28 [12479222.001]
  • [Cites] Adv Exp Med Biol. 2003;510:51-6 [12580404.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1012-9 [12615716.001]
  • [Cites] Mol Cancer Ther. 2003 Apr;2(4):383-8 [12700282.001]
  • [Cites] Oncology. 2003;64(4):380-8 [12759536.001]
  • [Cites] Microvasc Res. 2003 Sep;66(2):91-101 [12935767.001]
  • [Cites] Neurosci Res. 2004 Jan;48(1):13-20 [14687877.001]
  • [Cites] Physiol Behav. 2004 Jan;80(4):489-98 [14741234.001]
  • [Cites] Pflugers Arch. 2004 Feb;447(5):619-28 [12739169.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):437-47 [15170446.001]
  • [Cites] Cancer Res. 1966 Jan;26(1):143-8 [5901739.001]
  • [Cites] Biochem J. 1976 Feb 15;154(2):405-14 [7237.001]
  • [Cites] Biochemistry. 1979 Aug 7;18(16):3506-11 [38832.001]
  • [Cites] J Biol Chem. 1996 Sep 13;271(37):22810-4 [8798458.001]
  • [Cites] Arch Biochem Biophys. 1996 Nov 15;335(2):245-57 [8914921.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):409-15 [9033256.001]
  • [Cites] Am J Physiol. 1998 Jan;274(1 Pt 1):E102-7 [9458754.001]
  • [Cites] J Appl Physiol (1985). 1998 Mar;84(3):987-94 [9480961.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1237-44 [16434551.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8927-30 [16982728.001]
  • [Cites] Int J Pharm. 2006 Nov 15;325(1-2):48-54 [16887304.001]
  • [Cites] Mol Pharmacol. 2006 Dec;70(6):2108-15 [17000864.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11736-44 [17178869.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):913-23 [17158952.001]
  • [Cites] J Immunol. 2007 Feb 1;178(3):1505-11 [17237399.001]
  • [Cites] Pharm Res. 2007 Jun;24(6):1067-78 [17377745.001]
  • [Cites] Virchows Arch. 2008 Feb;452(2):139-46 [18188595.001]
  • [Cites] Science. 1989 Oct 27;246(4929):500-3 [2814477.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11081-5 [1662382.001]
  • [Cites] Free Radic Biol Med. 1995 Apr;18(4):641-7 [7750788.001]
  • [Cites] Experientia. 1996 May 15;52(5):464-8 [8641384.001]
  • [Cites] Semin Radiat Oncol. 1998 Jul;8(3):143-50 [9634491.001]
  • [Cites] Trends Biochem Sci. 1999 Feb;24(2):68-72 [10098401.001]
  • [Cites] Biochem J. 1999 Oct 15;343 Pt 2:281-99 [10510291.001]
  • [Cites] J Biol Chem. 1959 May;234(5):1036-41 [13654314.001]
  • [Cites] Neurosurgery. 2004 Dec;55(6):1410-9; discussion 1419 [15574223.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):632-7 [16423989.001]
  • [CommentIn] J Clin Invest. 2008 Dec;118(12):3835-7 [19033652.001]
  • (PMID = 19033663.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA56690; United States / NCI NIH HHS / CA / R21 CA091565; United States / NCI NIH HHS / CA / CA91565; United States / NCI NIH HHS / CA / P01 CA056690; United States / NCI NIH HHS / CA / CA40355; United States / NCI NIH HHS / CA / R01 CA040355
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Monocarboxylic Acid Transporters; 0 / Symporters; 0 / monocarboxylate transport protein 1; 33X04XA5AT / Lactic Acid; IY9XDZ35W2 / Glucose; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC2582933
  •  go-up   go-down


63. Mariño-Enríquez A, González-Rocha T, Burgos E, Stolnicu S, Mendiola M, Nogales FF, Hardisson D: Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation: a clinicopathologic study of 5 cases and review of the literature. Hum Pathol; 2008 Nov;39(11):1606-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One tumor showed exclusively transitional cell differentiation, whereas the remaining 4 neoplasms showed that the transitional cell carcinoma was admixed with a variable proportions of endometrioid adenocarcinoma.
  • Four cases were in FIGO stage IB, whereas the remaining tumor infiltrated the uterine cervix (FIGO stage IIB).

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620731.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


64. FUTURE II Study Group: Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis; 2007 Nov 15;196(10):1438-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle (VLP) vaccine has been shown to be 95%-100% effective in preventing cervical and genital disease related to HPV-6, -11, -16, and -18 in 16-26-year-old women naive for HPV vaccine types.
  • RESULTS: Vaccination was 100% effective (95% confidence interval [CI], 79%-100%) in preventing incident cervical intraepithelial neoplasia 2 or 3 or cervical adenocarcinoma in situ caused by the HPV type or types for which the women were negative at enrollment.
  • [MeSH-minor] Adolescent. Adult. Antibodies, Viral / blood. Cervical Intraepithelial Neoplasia / prevention & control. Cervical Intraepithelial Neoplasia / virology. DNA, Viral / analysis. Double-Blind Method. Enzyme-Linked Immunosorbent Assay. Female. Humans. Injections, Intramuscular. Polymerase Chain Reaction. Prospective Studies. Treatment Outcome. Uterine Cervical Neoplasms / prevention & control. Uterine Cervical Neoplasms / virology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Infect Dis. 2007 Nov 15;196(10):1431-2 [18008218.001]
  • (PMID = 18008221.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral; 0 / Papillomavirus Vaccines
  •  go-up   go-down


65. Liang J, Mittal KR, Wei JJ, Yee H, Chiriboga L, Shukla P: Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions. Int J Gynecol Pathol; 2007 Jan;26(1):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions.
  • Early detection of premalignant and malignant glandular lesions of the uterine cervix and their distinction from benign mimics is crucial but sometimes difficult.
  • In this study, we investigated utility of expression of p16, CEA, Ki67, p53 and ER/PR in evaluating the benign, premalignant, and malignant glandular lesions of the uterine cervix.
  • A total of 35 cervical cone or LEEP cases were collected including 14 adenocarcinoma in situ (AIS), 7 endocervical glandular dysplasia (EGD), and 14 benign mimics (BM).
  • There was a loss of ER/PR in cervical AIS, but not in EGD.
  • Our results indicate that the Silverberg scoring system is a useful tool in differential diagnosis of cervical glandular lesions for increased diagnostic accuracy and interobserver agreement.
  • Most cervical glandular lesions can be differentiated by using a combination of histological scores with a panel of immunomarkers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Carcinoembryonic Antigen / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Diagnosis, Differential. Female. Humans. Ki-67 Antigen / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Suppressor Protein p53 / metabolism


66. Uzan C, Vincens E, Balleyguier C, Gouy S, Pautier P, Duvillard P, Haie-Meder C, Morice P: Outcome of patients with incomplete resection after surgery for stage IB2/II cervical carcinoma with chemoradiation therapy. Int J Gynecol Cancer; 2010 Apr;20(3):379-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with incomplete resection after surgery for stage IB2/II cervical carcinoma with chemoradiation therapy.
  • OBJECTIVE: Standard treatment of stage IB2/II cervical carcinoma is chemoradiation therapy.
  • (1) stage IB2/II cervical cancer, (2) external radiotherapy (45 Gy) with concomitant chemotherapy followed by uterovaginal brachytherapy (15 Gy), (3) magnetic resonance imaging performed between 3 and 8 weeks after brachytherapy, and (4) completion surgery with incomplete resection of pelvic disease.
  • The locations of the incomplete resection were (some patients had several locations) the parametrium (n = 4), lateral limit of the cervix (n = 4), anterior (n = 2), posterior (n = 3), and vagina (n = 2).
  • CONCLUSIONS: The prognosis is poor when resection is incomplete after chemoradiation therapy in advanced-stage cervical cancer, and further surgery does not seem to improve this outcome.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / therapy. Carcinoma, Squamous Cell / therapy. Hysterectomy. Uterine Cervical Neoplasms / therapy


67. Chan KK, Ip P, Kwong P, Tam KF, Ngan HY: A combination of chemoirradiation and chemotherapy for treatment of advanced clear cell adenocarcinoma of the cervix. Int J Gynecol Cancer; 2008 May-Jun;18(3):559-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination of chemoirradiation and chemotherapy for treatment of advanced clear cell adenocarcinoma of the cervix.
  • Clear cell adenocarcinoma of the cervix (CCAC) is an uncommon tumor.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brachytherapy / methods. Neoplasm Invasiveness / pathology. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692092.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Eitan R, Levavi H, Peled Y, Brenner R, Sabah G, Ben-Arie A, Dgani R, Fishman A, Sulkes A, Fenig E, Koren C: Should simple hysterectomy be added after chemo-radiation for stage IB2 and bulky IIA cervical carcinoma? Aust N Z J Obstet Gynaecol; 2010 Jun;50(3):289-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should simple hysterectomy be added after chemo-radiation for stage IB2 and bulky IIA cervical carcinoma?
  • BACKGROUND AND AIMS: Management of bulky cervical tumours is controversial.
  • We describe the addition of high dose rate brachytherapy with concomitant chemotherapy to an attenuated protocol of radiation followed by simple hysterectomy in the management of bulky cervical tumours.
  • METHODS: Between January, 2003 and December, 2006, 23 patients diagnosed with bulky cervical tumours underwent a fixed chemo-radiation protocol followed by simple hysterectomy.
  • On final pathology, 12 patients (52%) had a pathological complete response, whereas 11 patients (48%) had residual carcinoma in the cervix.
  • CONCLUSIONS: This attenuated protocol of chemo-radiation using HDR brachytherapy followed by simple hysterectomy is a viable option in the treatment of bulky cervical carcinomas.
  • The rate of residual cervical disease after chemo-radiation is substantial, but simple hysterectomy achieved negative surgical margins in all cases.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Hysterectomy. Uterine Cervical Neoplasms / surgery


69. Zhao C, Florea A, Austin RM: Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med; 2010 Jan;134(1):103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 75 cases with hrHPV+ AGC results, 13 (17.3%) had cervical intraepithelial neoplasia grades 2/3, 10 (13.3%) had adenocarcinoma in situ, and 3 (4.0%) had cervical invasive adenocarcinoma, whereas for 234 women with hrHPV(-) results, 1 (0.4%) had cervical intraepithelial neoplasia grades 2/3, 1 (0.4%) had adenocarcinoma in situ, 1 each (0.4%) had cervical adenocarcinoma and ovarian carcinoma, and 8 (3.4%) had endometrial carcinoma.
  • CONCLUSIONS: Positive hrHPV AGC results were most strongly associated with cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ in women younger than 50 years.
  • Positive hrHPV AGC results were also present in all 3 cases of invasive cervical adenocarcinoma in women younger than 50 years.
  • Of note, hrHPV(-) AGC results were present in 10 of 13 carcinomas (76.9%) detected after AGC Pap tests, all in women 40 years or older with endometrial adenocarcinomas (n = 8), ovarian carcinoma (n = 1), and cervical adenosquamous carcinoma in a woman (n = 1) in her 50s.
  • Testing for hrHPV after AGC Pap testing was most helpful in the detection of cervical intraepithelial neoplasia grades 2/3, adenocarcinoma in situ, and invasive cervical adenocarcinomas in women younger than 50 years.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. DNA, Viral. Papanicolaou Test. Papillomaviridae / genetics. Uterine Cervical Neoplasms / pathology. Vaginal Smears


70. Al-Beiti MA, Lu X, Liu XS: [Correlation of HIPK2 expression with HPV infection and apoptosis in cervical cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Jun;31(6):434-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of HIPK2 expression with HPV infection and apoptosis in cervical cancer].
  • OBJECTIVE: To evaluate the correlation of the expression of homeodomain-interacting protein kinase 2 (HIPK2) with human papillomavirus (HPV) infection and apoptosis in cervical cancer.
  • METHODS: Formalin-fixed, paraffin embedded tissue samples from 50 cervical cancers and 15 normal uterine cervix cases were obtained.
  • RESULTS: HIPK2 protein expression was detected in 88.0% (44/50) of cervical cancers and 6.7% (1/15) of normal cervical tissues.
  • HPV was found in 78.0% (39/50) of cervical cancers and 20.0% (3/15) of normal cervical tissue samples.
  • CONCLUSION: HIPK2 protein expression is positively correlated with HPV infection, but negatively with apoptotic index in cervical cancers.
  • Therefore, HIPK2 may be involved in the mechanism of apoptosis in cervical cancer and may play an important role in cervical carcinogenesis.
  • [MeSH-major] Apoptosis. Carcinoma, Squamous Cell / metabolism. Carrier Proteins / metabolism. Papillomavirus Infections. Protein-Serine-Threonine Kinases / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / virology. Cervix Uteri / metabolism. Female. Humans. Middle Aged. Papillomaviridae. Proliferating Cell Nuclear Antigen / metabolism

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950553.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 2.7.1.- / HIPK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


71. Horn LC, Hentschel B, Galle D, Bilek K: Extracapsular extension of pelvic lymph node metastases is of prognostic value in carcinoma of the cervix uteri. Gynecol Oncol; 2008 Jan;108(1):63-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracapsular extension of pelvic lymph node metastases is of prognostic value in carcinoma of the cervix uteri.
  • OBJECTIVES: Pelvic lymph node involvement is a well-recognized prognostic factor in cervical carcinoma (CX).
  • CONCLUSIONS: The results indicate that extracapsular spread (ECS) of pelvic lymph node metastases is of prognostic impact in cervical carcinomas.
  • [MeSH-major] Lymph Nodes / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis


72. Dufès C, Keith WN, Bilsland A, Proutski I, Uchegbu IF, Schätzlein AG: Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res; 2005 Sep 15;65(18):8079-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The systemic tumor necrosis factor alpha (TNFalpha) gene therapy was efficacious in the experimental treatment of established A431 epidermoid carcinoma, C33a cervix carcinoma, and LS174T colorectal adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / therapy. Animals. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / therapy. Cell Line, Tumor. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / therapy. Female. Humans. Lac Operon. Nanostructures / chemistry. Plasmids / genetics. Promoter Regions, Genetic. Transfection / methods. Tumor Necrosis Factor-alpha / genetics. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / therapy. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166279.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Polypropylenes; 0 / Tumor Necrosis Factor-alpha; 0 / poly(propyleneimine)
  •  go-up   go-down


73. Sameshima H, Nagai K, Ikenoue T: Single vaginal ectopic ureter of fetal metanephric duct origin, ipsilateral kidney agenesis, and ipsilateral rudimentary uterine horn of the bicornuate uterus. Gynecol Oncol; 2005 Apr;97(1):276-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single vaginal ectopic ureter of fetal metanephric duct origin, ipsilateral kidney agenesis, and ipsilateral rudimentary uterine horn of the bicornuate uterus.
  • CASE: Two Japanese women had a single ectopic ureter opening in the central wall of the vagina, ipsilateral kidney agenesis, and ipsilateral rudimentary uterine horn of the bicornuate uterus.
  • One had squamous cell carcinoma of the uterine cervix, and the other had adenocarcinoma of the vagina arising from the ectopic ureter meatus, which was histologically confirmed as fetal metanephric duct remnant.
  • Clinically, the ectopic vaginal ureter is important as a possible background of vaginal adenocarcinoma, and information on the ureter-like duct course is required during surgery.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Kidney / abnormalities. Ureter / abnormalities. Uterine Cervical Neoplasms / etiology. Uterus / abnormalities. Vaginal Neoplasms / etiology


74. Ozmen O, Haligur M, Kocamuftuoglu M: Clinocopathologic and immunohistochemical findings of multiple genital leiomyomas and mammary adenocarcinomas in a bitch. Reprod Domest Anim; 2008 Jun;43(3):377-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinocopathologic and immunohistochemical findings of multiple genital leiomyomas and mammary adenocarcinomas in a bitch.
  • Abdominal ultrasonography demonstrated a large mid-abdominal mass at the distal part of the left uterine horn.
  • Also multiple masses in the cervix and vagina were found.
  • At the necropsy numerous masses were seen at the vagina and cervix and one big mass seen at the left cornu uteri.
  • Histopathological diagnosis was leiomyoma.
  • Histopathologically, mammary tumours were diagnosed as complex type tubulopapillary adenocarcinoma.
  • The objectives of this study were to measure the proliferation indices in canine complex type mammary adenocarcinoma and genital leiomyomas using immunohistochemical detection of Ki-67 and proliferating cell nuclear antigen to determine the relationship of these antigens to clinical and pathologic variables; and to examine the immunoreactivity of these tumours with different markers.
  • [MeSH-major] Adenocarcinoma / veterinary. Dog Diseases / pathology. Leiomyomatosis / veterinary. Mammary Neoplasms, Animal / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18226017.001).
  • [ISSN] 1439-0531
  • [Journal-full-title] Reproduction in domestic animals = Zuchthygiene
  • [ISO-abbreviation] Reprod. Domest. Anim.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


75. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodill A, Green J, Peto J, Plummer M, Sweetland S: Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer; 2006 Mar 15;118(6):1481-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies.
  • Tobacco smoking has been classified as a cause of cervical cancer, but the effect of different patterns of smoking on risk is unclear.
  • The International Collaboration of Epidemiological Studies of Cervical Cancer has brought together and combined individual data on 13,541 women with and 23,017 women without cervical carcinoma, from 23 epidemiological studies.
  • Relative risks (RRs) and 95% confidence intervals (CIs) of carcinoma of the cervix in relation to tobacco smoking were calculated with stratification by study, age, sexual partners, age at first intercourse, oral contraceptive use and parity.
  • Current smokers had a significantly increased risk of squamous cell carcinoma of the cervix compared to never smokers (RR = 1.60 (95% CI: 1.48-1.73), p<0.001).
  • There was no association between smoking and adenocarcinoma of the cervix (RR = 0.89 (0.74-1.06) and 0.89 (0.72-1.10) for current and past smokers respectively), and the differences between the RRs for smoking and squamous cell and adenocarcinoma were statistically significant (current smoking p<0.001 and past smoking p = 0.01).
  • Eight of the studies had tested women for cervical HPV-DNA, and in analyses restricted to women who tested positive, there was a significantly increased risk in current compared to never smokers for squamous cell carcinoma (RR = 1.95 (1.43-2.65)), but not for adenocarcinoma (RR = 1.06 (0.14-7.96)).
  • In summary, smokers are at an increased risk of squamous cell but not of adenocarcinoma of the cervix.
  • [MeSH-major] Smoking / epidemiology. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206285.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral
  •  go-up   go-down


76. Moodley M, Moodley K: Trends of histopathology of cervical cancer among women in Durban, South Africa. Eur J Gynaecol Oncol; 2009;30(2):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends of histopathology of cervical cancer among women in Durban, South Africa.
  • INTRODUCTION: Cervical squamous cell carcinoma has traditionally been the commonest histological type of cervical cancer.
  • Adenocarcinoma has recently been reported to occur with increasing frequency.
  • METHODS: This retrospective study was conducted on 2,930 patients with cervical cancer over an eight-year period (1995-2002) recruited from the combined Gynaecology Oncology Clinic at King Edward VIII Hospital (KEH), Pathology Laboratories at KEH, and from the private sector.
  • RESULTS: In the public sector squamous cell carcinoma was found to be the commonest type of cervical cancer irrespective of ethnicity and age.
  • In the private sector, a slightly higher proportion (38.8%) of women had adenocarcinoma, however since the total number of patients were small (85) there was no statistically significant increase in adenocarcinoma relative to squamous cell carcinoma.
  • There was no correlation between the documented risk factors i.e., smoking, contraception and human papillomavirus and histological type of cervical cancer.
  • Similarly, there was no statistically significant relationship between ethnicity, differentiation, type of cervical cancer and age of the patient in both sectors.
  • CONCLUSION: This study has not revealed an increasing incidence in cervical adenocarcinoma in the public setting.
  • However, in the private sector, a significant proportion of black women (38.8%) had adenocarcinoma.
  • All Asian women had adenocarcinoma while 25% of the white women had adenocarcinoma.
  • [MeSH-major] Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Child, Preschool. Female. Humans. Middle Aged. South Africa / epidemiology. Young Adult


77. Kim HG, Song H, Yoon DH, Song BW, Park SM, Sung GH, Cho JY, Park HI, Choi S, Song WO, Hwang KC, Kim TW: Cordyceps pruinosa extracts induce apoptosis of HeLa cells by a caspase dependent pathway. J Ethnopharmacol; 2010 Mar 24;128(2):342-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM OF THE STUDY: Cordyceps is a parasitic fungus and has long been used as a traditional Chinese medicine to treat illnesses, promote longevity, increase athletic power, and relieve exhaustion and cancer.
  • In this study, we reveal the mechanisms underlying apoptosis induced by Cordyceps pruinosa butanol fraction (CPBF) in the human cervical adenocarcinoma cell line, HeLa.
  • CONCLUSIONS: These results indicate that apoptotic effects of CPBF on HeLa cells are mediated by mitochondria-dependent death-signaling pathway independent of reactive oxygen species, suggesting that CPBF might be effective as an anti-proliferative agent for cancer.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20138133.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cytochrome c Group; 0 / Plant Extracts; 0 / Reactive Oxygen Species; 0 / bcl-2-Associated X Protein; 116110-46-4 / cytochrome c''; 9007-43-6 / Cytochromes c; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


78. Sonoda K, Miyamoto S, Nakashima M, Wake N: The biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. Front Biosci; 2008;13:1106-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RCAS1 is a receptor-binding cancer antigen which is expressed on human uterine cervical adenocarcinoma cell line (SiSo).
  • Finding a correlation between the expression of this gene and the overall survival of patients with 14 different types of cancer points to the clinical significance of this gene.
  • Moreover, the expression RCAS1 correlates with other clinicopathological parameters including the histological type of cancer, its differentiation, tumor size, clinical stage, the depth of invasion, lymphovascular space involvement, lymph node metastasis, and positive peritoneal cytological results.
  • The concentration of RCAS1 in serum or pleural effusions has been found to be significantly higher in patients with several different types of cancer as compared to normal controls.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981616.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / EBAG9 protein, human; 0 / Tn antigen
  • [Number-of-references] 78
  •  go-up   go-down


79. Tawfik El-Mansi M, Williams AR: Validation of tissue microarray technology using cervical adenocarcinoma and its precursors as a model system. Int J Gynecol Cancer; 2006 May-Jun;16(3):1225-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of tissue microarray technology using cervical adenocarcinoma and its precursors as a model system.
  • We used a large series of cervical adenocarcinomas to investigate TMA technology in assessment of immunohistochemical staining.
  • A TMA was constructed using 273 archival paraffin blocks from 139 patients with 119 invasive and 20 adenocarcinoma in situ and 16 normal controls.
  • Our results suggest that TMAs can be successfully used for immunohistochemical studies of cervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Microarray Analysis / methods. Tissue Array Analysis / methods. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / analysis. Carcinoma in Situ / diagnosis. Carcinoma in Situ / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Female. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Models, Biological. Molecular Diagnostic Techniques. Neoplasm Invasiveness / diagnosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803510.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


80. Hurrell DP, Jamison J, Dobbs SP, McCluggage WG: Cervical adenocarcinoma in situ recurring as vaginal adenocarcinoma 16 years after hysterectomy. Int J Gynecol Pathol; 2009 May;28(3):296-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenocarcinoma in situ recurring as vaginal adenocarcinoma 16 years after hysterectomy.
  • We report a case in which a vaginal adenocarcinoma was discovered in a 67-year-old woman 16 years after hysterectomy for cervical adenocarcinoma in situ.
  • Both the vaginal and cervical lesions exhibited morphologic and immunohistochemical (CDX2-positive) features of intestinal differentiation.
  • Linear array human papillomavirus genotyping demonstrated the vaginal adenocarcinoma to contain human papillomavirus 45.
  • We believe the vaginal adenocarcinoma to be related to the cervical adenocarcinoma in situ and to represent recurrence of this.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Neoplasm Recurrence, Local / pathology. Uterine Cervical Neoplasms / pathology. Vaginal Neoplasms / pathology


81. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH: Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix. Br J Cancer; 2010 Jun 8;102(12):1692-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix.
  • BACKGROUND: To determine the prognostic factors and treatment outcomes of patients with early-stage adenocarcinoma (AdCa) of uterine cervix who underwent radical hysterectomy (RH).
  • METHODS: Patients with early-stage squamous cell carcinoma (SCCa) of the uterine cervix who underwent RH were compared with patients with AdCa by multivariate analysis.
  • [MeSH-major] Adenocarcinoma / surgery. Hysterectomy / methods. Uterine Cervical Neoplasms / surgery


82. Nagai N, Hirata E, Kusuda T, Mukai K, Arihiro K, Ohama K: Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report.
  • Villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix is a rare neoplasm, and its treatment has rarely been reported.
  • Thus, the combination of docetaxel and cisplatin is suggested to be useful for neoadjuvant chemotherapy of cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343210.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


83. Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO, Gynecologic Oncology Group: Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol; 2008 Jul;110(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
  • OBJECTIVE: To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the cervix that failed on higher priority treatment protocols and to determine the nature and degree of toxicity.
  • Patients must have had advanced or recurrent measurable carcinoma of the cervix, and failed one prior chemotherapy regimen.
  • CONCLUSION: Pemetrexed at this dose and schedule showed moderate activity against advanced or recurrent cervical cancer that has failed prior chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Dexamethasone / therapeutic use. Disease Progression. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Middle Aged. Neoplasm Recurrence, Local. Patient Selection. Pemetrexed. Treatment Outcome


84. Nijhuis ER, van der Zee AG, in 't Hout BA, Boomgaard JJ, de Hullu JA, Pras E, Hollema H, Aalders JG, Nijman HW, Willemse PH, Mourits MJ: Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys; 2006 Nov 1;66(3):699-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery.
  • PURPOSE: The aim of this study was to evaluate efficacy of gynecologic examination under general anesthesia with cervical biopsies after (chemo) radiation for cervical cancer to identify patients with residual disease who may benefit from salvage surgery.
  • METHODS AND MATERIALS: In a retrospective cohort study data of all cervical cancer patients with the International Federation of Gynecology and Obstetrics (FIGO) Stage IB1 to IVA treated with (chemo) radiation between 1994 and 2001 were analyzed.
  • Cervical biopsy samples were taken from patients judged to be operable.
  • In case of residual cancer, salvage surgery was performed.
  • RESULTS: Between 1994 and 2001, 169 consecutive cervical cancer patients received primary (chemo) radiation, of whom 4 were lost to follow-up.
  • CONCLUSIONS: Gynecologic examination under anesthesia 8 to 10 weeks after (chemo) radiation with cervical biopsies allows identification of those cervical cancer patients who have residual local disease, of whom a small but significant proportion may be salvaged by surgery.
  • [MeSH-major] Cervix Uteri / pathology. Salvage Therapy. Uterine Cervical Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Anesthesia, General. Biopsy. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm, Residual. Retrospective Studies. Survival Analysis


85. Zafrakas M, Papanikolaou AN, Venizelos ID, Kellartzis D, Agorastos T, Bontis JN: A rare case of renal cell carcinoma metastasizing to the uterine cervix. Eur J Gynaecol Oncol; 2009;30(2):239-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of renal cell carcinoma metastasizing to the uterine cervix.
  • Metastatic tumors to the uterine cervix originating from malignancies in other organs are very rare.
  • A case of a 45-year-old white woman presenting with vaginal bleeding, due to renal cell carcinoma metastasizing to the cervix, is reported.
  • The patient had been treated four years and five months earlier due to two primary malignancies: colon adenocarcinoma and renal cell carcinoma.
  • The possibility of metastasis from another primary should be considered in the differential diagnosis of tumors of the uterine cervix in order to plan optimal management.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Uterine Cervical Neoplasms / secondary


86. Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, Nishimura R: Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol; 2007 May;31(5):664-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix.
  • Endocervical-type mucinous adenocarcinoma (ECA) of the uterine cervix is defined as a tumor composed of cells resembling those of the endocervical glands, but recent studies have demonstrated that a minority of ECAs displays a gastric immunophenotype.
  • Fifty-three cases of mucinous adenocarcinoma of the uterine cervix (37 FIGO stage IB, 4 stage IIA, and 12 stage IIB) were reviewed and reevaluated using a newly established morphologic criteria for distinguishing gastric type adenocarcinoma, which was defined as a tumor showing clear and/or pale eosinophilic and voluminous cytoplasm, with distinct cell borders.
  • Following the current World Health Organization scheme (2003), 47 tumors (89%) were classified as ECA, 1 (2%) as intestinal type, 1 (2%) as mixed endocervical and intestinal type, and 4 (8%) as minimal deviation adenocarcinoma.
  • Twelve of 47 (26%) ECAs and all 4 minimal deviation adenocarcinomas, reclassified as gastric type using the novel criteria, were frequently positive for HIK1083 with a rate of 75% (12/16), whereas only 11% (4/37) of nongastric tumors were positive.
  • Patients with gastric-type adenocarcinomas had a significantly decreased 5-year disease-specific survival rate (30 vs. 77%; P<0.0001), and the gastric type morphology was related to a significant risk for disease recurrence compared with the nongastric type (P=0.001; HR, 4.5; 95% confidence interval, 1.42-14.2).
  • Mucinous adenocarcinoma of the uterine cervix with gastric immunophenotype can be a distinct morphologic variant showing an aggressive clinical course.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Gastric Mucosa / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460448.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Gastric Mucins
  •  go-up   go-down


87. Duska LR: Can we improve the detection of glandular cervical lesions: the role and limitations of the Pap smear diagnosis atypical glandular cells (AGC). Gynecol Oncol; 2009 Sep;114(3):381-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can we improve the detection of glandular cervical lesions: the role and limitations of the Pap smear diagnosis atypical glandular cells (AGC).
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / pathology. Vaginal Smears / standards
  • [MeSH-minor] Cervical Intraepithelial Neoplasia / pathology. Female. Humans


88. Nara M, Hashi A, Murata S, Kondo T, Yuminamochi T, Nakazawa K, Katoh R, Hoshi K: Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection. Gynecol Oncol; 2007 Aug;106(2):289-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection.
  • OBJECTIVES: The aim of this study was to investigate differences in the process of carcinogenesis between adenocarcinoma coexistent with LEGH and conventional adenocarcinoma.
  • METHODS: Using the surgical pathology files of patients who visited the University of Yamanashi Hospital, Yamanashi Central Hospital and Kofu Municipal Hospital between 1996 and 2005, pathological diagnoses were reevaluated based on criteria for the diagnosis of LEGH by Nucci et al.
  • As for the cases including adenocarcinoma with LEGH: (a) we created a map showing position of the LEGH component and adenocarcinoma component and squamo-columnar junction (SCJ) in HE-stained specimens, (b) immunohistochemical staining was performed using antibodies to CEA, HIK1083 and p53, and (c) detection of HPV DNA was performed using PCR and in situ hybridization (ISH).
  • RESULTS: Endocervical adenocarcinoma was observed coexistent with LEGH in 5 cases (19.2%). (a) LEGH was located in a remote place from the SCJ.
  • Sizes of lesions in the 5 cases ranged from 18 to 35 mm in width and 7 to 16 mm in depth. (b) HIK1083 was diffusely immunopositive in the cytoplasm of LEGH component and focal immunopositive in 4 cases with adenocarcinoma component.
  • Immunopositivity for CEA was seen in the cytoplasm of adenocarcinoma component in 4 cases.
  • Immunopositivity for p53 was seen in adenocarcinoma component nuclei in 2 cases. (c) HPV DNA was not detected using PCR and ISH in either LEGH or adenocarcinoma components.
  • CONCLUSIONS: The present study suggests that clear differences exist in the process of carcinogenesis between adenocarcinoma associated with LEGH and conventional adenocarcinoma.
  • LEGH may represent a precursor of cervical adenocarcinoma independent of HPV infection.
  • As LEGH displays characteristics of precancerous mucinous adenocarcinoma, surgical treatment should be considered for LEGH growing beyond a certain size.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Neoplasms, Glandular and Epithelial / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


89. Belval CC, Barranger E, Dubernard G, Touboul E, Houry S, Daraï E: Peritoneal carcinomatosis after laparoscopic radical hysterectomy for early-stage cervical adenocarcinoma. Gynecol Oncol; 2006 Sep;102(3):580-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal carcinomatosis after laparoscopic radical hysterectomy for early-stage cervical adenocarcinoma.
  • BACKGROUND: The risk of wound metastasis after laparoscopic management of early-stage cervical cancer is well known, but there are few data on peritoneal carcinomatosis of cervical adenocarcinoma.
  • CASE: We report the first case of peritoneal carcinomatosis occurring in a woman with FIGO stage Ib1 cervical adenocarcinoma who underwent laparoscopic type III radical hysterectomy and bilateral pelvic lymphadenectomy (sentinel node procedure) followed by vaginal brachytherapy.
  • CONCLUSION: Laparoscopy for cervical adenocarcinoma may carry a risk of peritoneal dissemination.
  • [MeSH-major] Adenocarcinoma / surgery. Hysterectomy. Peritoneal Neoplasms / secondary. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624387.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Hatami M, Del Priore G, Chudnoff SG, Goldberg GL: Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy. Arch Iran Med; 2006 Oct;9(4):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy.
  • A 32-year-old female was diagnosed by loop electrosurgical excision procedure with adenocarcinoma in situ and a focus suspicious for positive lympho-vascular invasion.
  • We concluded that abdominal radical trachelectomy may be a surgical option for early stage cervical cancer treatment in young women who wish to preserve fertility.
  • [MeSH-major] Adenocarcinoma / surgery. Gynecologic Surgical Procedures / methods. Lymph Node Excision / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Cervix Uteri / surgery. Electrosurgery. Female. Fertility. Humans. Intraoperative Complications. Postoperative Complications. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061618.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


91. McCluggage WG, Harley I, Houghton JP, Geyer FC, MacKay A, Reis-Filho JS: Composite cervical adenocarcinoma composed of adenoma malignum and gastric type adenocarcinoma (dedifferentiated adenoma malignum) in a patient with Peutz Jeghers syndrome. J Clin Pathol; 2010 Oct;63(10):935-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite cervical adenocarcinoma composed of adenoma malignum and gastric type adenocarcinoma (dedifferentiated adenoma malignum) in a patient with Peutz Jeghers syndrome.
  • An unusual cervical adenocarcinoma is reported in a 50-year-old woman with a history of Peutz Jeghers syndrome.
  • The carcinoma contained two morphologically distinct and spatially separate components, one comprising typical well differentiated adenoma malignum and the other a moderately differentiated neoplasm, in keeping with gastric type adenocarcinoma.
  • It is believed that the component of gastric type adenocarcinoma arose through a process of dedifferentiation within adenoma malignum and we provide circumstantial molecular evidence in support of the interpretation that both components may be clonally related in that they displayed an extra copy of chromosome 7.
  • This raises the possibility of a relationship between these two uncommon types of cervical adenocarcinoma, both of which are thought to exhibit gastric differentiation.
  • [MeSH-major] Adenocarcinoma / pathology. Mixed Tumor, Malignant / pathology. Peutz-Jeghers Syndrome / pathology. Uterine Cervical Neoplasms / pathology


92. Pruski D, Kedzia W, Przybylski M, Józefiak A, Purol M, Spaczyński M: [Assessment of optoelectronic method and molecular test usefulness for cervical intraepithelial neoplasia and cervical cancer detection]. Ginekol Pol; 2010 Jun;81(6):426-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of optoelectronic method and molecular test usefulness for cervical intraepithelial neoplasia and cervical cancer detection].
  • INTRODUCTION: Biophysics and molecular biology are disciplines dynamically entering the area of cervical cancer prevention.
  • The combined test, comprising optoelectronic and molecular diagnostics, may play a significant role in the decrease of cervical cancer incidence and mortality.
  • OBJECTIVE: Assessment of the combined test usefulness--optoelectronic method and HPV test for the presence of oncogenic HPV types, in the detection of cervical intraepithelial neoplasia and cervical cancer.
  • MATERIAL AND METHOD: From August 2006 to October 2008 the study included 250 patients from the Laboratory of Pathophysiology of Uterine Cervix in Gynecology and Obstetrics Clinical Hospital of Karol Marcinkowski University of Medical Sciences.
  • RESULTS: Sensitivity of the combined test for low-grade intraepithelial changes in the area of squamous epithelium (CIN 1) was 81%, while for high-grade changes (CIN 2, CIN 3) and carcinoma planoepitheliale together with adenocarcinoma was 100%.
  • CONCLUSIONS: Optoelectronic and molecular diagnostics methods are useful in detecting neoplastic cervical changes.
  • Both methods may become a key diagnostic tool of basic and advanced level of cervical screening.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. Cervix Uteri / pathology. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Vaginal Smears / instrumentation. Vaginal Smears / methods
  • [MeSH-minor] Colposcopy. Female. Humans. Optics and Photonics. Poland. Precancerous Conditions / diagnosis. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


93. Barreth D, Schepansky A, Capstick V, Johnson G, Steed H, Faught W: Atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): a result not to be ignored. J Obstet Gynaecol Can; 2006 Dec;28(12):1095-1098
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective of this study was to determine the risk of a clinically significant lesion associated with the diagnosis of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H) on cervical cytology (Pap smear).
  • A computerized database containing cytologic and histologic information for the health region was used to identify women with a diagnosis of ASC-H on a Pap smear performed between January 1 and December 31, 2002.
  • Patients were excluded if they had a diagnosis of cervical cancer, adenocarcinoma in situ (AIS), or high-grade squamous intraepithelial lesion (HSIL) prior to the index Pap smear.
  • Ninety-one patients had a previous diagnosis of cervical cancer, AIS, or HSIL and were excluded from analysis, and 12 patients on review did not have ASC-H.
  • In this group, the rates of histologically proven cervical lesions were 2.9% (15/517) for cervical cancer, 1.7% (9/517) for AIS, and 65.6% (339/517) for HSIL.
  • CONCLUSION: The diagnosis of ASC-H on Pap smear is associated with an appreciable risk of clinically significant disease.
  • Patients with an ASC-H Pap smear result should undergo timely colposcopic and histologic assessment to rule out HSIL, AIS, and cervical cancer.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. Neoplasms, Squamous Cell / diagnosis. Precancerous Conditions / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Factors. Colposcopy. Diagnosis, Differential. Female. Humans. Middle Aged. Papanicolaou Test. Risk Factors. Vaginal Smears


94. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens. J Med Assoc Thai; 2008 Sep;91(9):1313-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens.
  • OBJECTIVE: To evaluate the hysterectomy specimen findings in the patients who underwent fractional curettage (F&C) with presence of adenocarcinoma in both endocervical and endometrial specimens.
  • MATERIAL AND METHOD: Forty-one patients who had adenocarcinoma in both endocervical and endometrial specimens from F&C and underwent subsequent hysterectomy for surgical staging without pre-operative radiotherapy or chemotherapy at King Chulalongkorn Memorial Hospital between 1999 and 2007 were evaluated Histologic slides from both F&C and hysterectomy specimens were reviewed and assessed All cases of endometrial adenocarcinoma with cervical involvement (stage 2) in hysterectomy specimens were also assessed and compared to the results in F&C specimens.
  • RESULTS: Fifteen patients (36.6%) with both positive endocervical and endometrial specimens from F&C were diagnosed as endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Only 34.1% of cases were endometrial carcinomas with cervical involvement.
  • In the 35 cases with endometrial carcinoma stage 2, 60% had adenocarcinoma in both endocervical and endometrial specimens from F&C.
  • CONCLUSION: In the patients who had adenocarcinoma in both endocervical and endometrial specimens from fractional curettage, the most common final pathological diagnosis from hysterectomy specimens was endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Therefore, only 60% of endometrial carcinoma stage 2 revealed positive adenocarcinoma in both endocervical and endometrial specimens from fractional curettage.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Dilatation and Curettage. Endometrial Neoplasms / pathology. Endometrium / pathology. Hysterectomy


95. Pettersson BF, Andersson S, Hellman K, Hellström AC: Invasive carcinoma of the uterine cervix associated with pregnancy: 90 years of experience. Cancer; 2010 May 15;116(10):2343-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive carcinoma of the uterine cervix associated with pregnancy: 90 years of experience.
  • BACKGROUND: This study is a representation of 90 years of experience with carcinoma of the uterine cervix in pregnancy.
  • The objective was to retrospectively study changes in the distribution of cervical carcinoma (CC) by age, disease stage, histopathology, survival, and the development of second primary cancers.
  • At the time of diagnosis, stage I CC was observed in 75.6% of patients during 1960 to 2004 compared with 24.8% of patients during 1914 to 1943.
  • [MeSH-major] Pregnancy Complications, Neoplastic / epidemiology. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Age Factors. Female. Humans. Incidence. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Second Primary / epidemiology. Neoplasms, Squamous Cell / epidemiology. Neoplasms, Squamous Cell / mortality. Neoplasms, Squamous Cell / pathology. Pregnancy. Survivors


96. Poujade O, Morice P, Rouzier R, Madelenat P, Lecuru F, Muray JM, Mathevet P, Alran S, Salmon RJ, Reyal F: Pathologic response rate after concomitant neo-adjuvant radiotherapy and chemotherapy for adenocarcinoma of the uterine cervix: a retrospective multicentric study. Int J Gynecol Cancer; 2010 Jul;20(5):815-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic response rate after concomitant neo-adjuvant radiotherapy and chemotherapy for adenocarcinoma of the uterine cervix: a retrospective multicentric study.
  • INTRODUCTION: Exclusive chemoradiotherapy (including brachytherapy) is the current standard of care for locoregionally advanced cervical cancer.
  • The aim of the present study was to evaluate the responsiveness and to identify factors predicting the response to concomitant chemoradiotherapy before surgery in cervical adenocarcinoma.
  • A total of 54 women with cervical adenocarcinoma stage IB2 to IIIB who had undergone concurrent chemoradiation therapy followed by surgical treatment were included.
  • RESULTS: The median (SD) age at diagnosis was 44.2 (12.4) years (range, 19.3-77 years).
  • CONCLUSIONS: Identification of predictive markers associated with incomplete response to neoadjuvant chemoradiotherapy in cervical adenocarcinoma may prove clinically useful and implement an individualized treatment plan.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Gynecologic Surgical Procedures. Radiotherapy, Adjuvant. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20606528.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


97. Kamaté B, Traoré CB, Diallo D, Sacko R, Toure M, Keita B, Teguete B, Traore Y, Diarra MH, Ouattara AT, Traoré AC, Mariko H, Dembele Y, Togola B, Tall K, Sanogo A, Diané M, Kaloga I, Traoré M, Dolo AI, Bayo S: [Extension of cervix cancer screening by visual methods to the community health centres in the district of Bamako]. Mali Med; 2008;23(4):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extension of cervix cancer screening by visual methods to the community health centres in the district of Bamako].
  • [Transliterated title] Extension du depistage du cancer du col uterin par inspection visuelle aux centres de sante communautaires du district de Bamako.
  • Cervix cancer remains a public health problem in developing countries.
  • These results are an assessment for multicentric study based on visual inspection of the cervix after application of acetiq acid (VIA) and lugol's iodine (VILI).
  • At all 177 biopsies were done, and histological diagnosis were: 67 dysplasias, 3 early invasive carcinomas, 69 invasive carcinomas and 38 inflammatory metaplasic lesions or nonconclusives aspects.
  • This study showed that screening of cervical cancer by visual inspection is workable at CSCOM level.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Community Health Centers / organization & administration. Mass Screening / organization & administration. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Acetic Acid. Adult. Biopsy. Coloring Agents. Female. Health Services Accessibility. Hospitals, University / organization & administration. Hospitals, University / statistics & numerical data. Humans. Iodides. Mali / epidemiology. Metaplasia. Middle Aged. Physical Examination. Prospective Studies. Staining and Labeling. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Dysplasia / epidemiology. Uterine Cervicitis / diagnosis. Uterine Cervicitis / epidemiology


98. Arellano-Llamas A, Garcia FJ, Perez D, Cantu D, Espinosa M, De la Garza JG, Maldonado V, Melendez-Zajgla J: High Smac/DIABLO expression is associated with early local recurrence of cervical cancer. BMC Cancer; 2006;6:256
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High Smac/DIABLO expression is associated with early local recurrence of cervical cancer.
  • BACKGROUND: In a recent pilot report, we showed that Smac/DIABLO mRNA is expressed de novo in a subset of cervical cancer patients.
  • We have now expanded this study and analyzed Smac/DIABLO expression in the primary lesions in 109 cervical cancer patients.
  • Seventy-eight samples corresponded to epidermoid cervical cancer and 31 to cervical adenocarcinoma.
  • RESULTS: Smac/DIABLO was expressed in more adenocarcinoma samples than squamous tumours (71% vs 50%; p = 0.037).
  • CONCLUSION: Smac/DIABLO expression is a potential marker for local recurrence in cervical squamous cell carcinoma patients.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / chemistry. Intracellular Signaling Peptides and Proteins / analysis. Mitochondrial Proteins / analysis. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / chemistry. Uterine Cervical Neoplasms / chemistry


99. Jiang L, Malpica A, Deavers MT, Guo M, Villa LL, Nuovo G, Merino MJ, Silva EG: Endometrial endometrioid adenocarcinoma of the uterine corpus involving the cervix: some cases probably represent independent primaries. Int J Gynecol Pathol; 2010 Mar;29(2):146-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial endometrioid adenocarcinoma of the uterine corpus involving the cervix: some cases probably represent independent primaries.
  • The majority of endometrial endometrioid adenocarcinomas involving the cervix have tumor morphology that is similar in the endometrium and the endocervix.
  • We selected 14 cases of endometrial endometrioid adenocarcinomas involving the cervix with complete pathology material available from the years between 1968 and 2004.
  • Histologic features varied between the tumors in the endometrium and the endocervix in 8 cases, and 5 of these cases had uniform, dilated glands having a microcystic appearance in the cervix.
  • The immunohistochemical studies showed some differences between the endometrial and endocervical adenocarcinomas in 8 of the 12 cases, independent of differing or similar histologic features.
  • Clonality studies showed differences between the adenocarcinoma in the endometrium and the endocervix in 7 cases, including 5 cases with different histologic appearances; 2 cases had similar loss of heterozygosity patterns.
  • However, endometrial tumors involving the cervix and endocervical tumors unrelated to HPV are both negative for high-risk HPV.
  • [MeSH-major] Carcinoma, Endometrioid / virology. Endometrial Neoplasms / virology. Papillomaviridae / genetics. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173500.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


100. Lee HB, Lee YS, Lee KH, Kim CJ, Park JS: A case of advanced gynecologic pelvic tumors showing the diagnostic utility of HPV analysis. J Gynecol Oncol; 2009 Dec;20(4):251-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This may lead to difficulties in determining the origin of the cancer and to distinguish a synchronous neoplasm from a metastatic cancer in advanced cases.
  • Recently, we treated a 59-year-old patient with adenocarcinoma of the uterine cervix, endometrium, fallopian tubes, and ovaries.
  • It was difficult to determine whether the cancer was a single origin metastatic cancer or a synchronous neoplasm.
  • The patient was finally diagnosed with metastatic cancer that originated from the uterine cervix by human papillomavirus (HPV) test.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):281-94 [15725796.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):337-41 [10053104.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):829-36 [15010819.001]
  • [Cites] Tumour Biol. 2003 Nov-Dec;24(6):310-6 [15004491.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):246-50 [11166153.001]
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):672-5 [12915876.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):104-11 [12468350.001]
  • [Cites] Obstet Gynecol. 2002 Nov;100(5 Pt 2):1129-33 [12423833.001]
  • [Cites] Cancer Causes Control. 2001 May;12(4):335-41 [11456229.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):7-12 [14668543.001]
  • (PMID = 20041104.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2799026
  • [Keywords] NOTNLM ; Cervical adenocarcinoma / Human papillomavirus / Metastatic cancer / Synchronous neoplasm
  •  go-up   go-down






Advertisement